INHIBITION OF HUMAN INTEGRIN ALPHA4BETA7

Description

RELATED APPLICATION

[0001] This application claims benefit of priority to U.S. Provisional Patent Application No. 62 / 916,062, filed October 16, 2019.TECHNICAL FIELD

[0002] Disclosed are novel compounds useful for the inhibition of the α 4 β 7 integrin. The compounds disclosed herein are applicable to the development of medicaments for the treatment of α 4 β 7 integrin-mediated conditions, such as inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD).BACKGROUND

[0003] Integrins are noncovalently associated α / β heterodimeric cell surface receptors involved in numerous cellular processes. Differential expression of integrins can regulate a cell's adhesive properties, allowing different leukocyte populations to be recruited to specific organs in response to different inflammatory signals. The α 4 integrins, including α 4 β 7 , play a role in lymphocyte migration throughout the gastrointestinal tract. They are expressed on most leukocytes, including B and T lymphocytes, where they mediate cell adhesion via selective binding to its primary ligand, mucosal addressin cell adhesion molecule (MAdCAM). Memory T lymphocytes expressing the α 4 β 7 integrin preferentially migrate into the gastrointestinal tract via firm adhesion to mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1).

[0004] Inhibitors of specific integrin-ligand interactions have been used for the treatment of various diseases. For example, monoclonal antibodies displaying high binding affinity for α 4 β 7 have displayed therapeutic benefits for gastrointestinal auto-inflammatory / autoimmune diseases, such as Crohn's disease, and ulcerative colitis. However, these therapies also have certain undesirable properties for the patient. A monoclonal antibody α 4 β 7 integrin inhibitor is administered by parenteral administration, has a long half-life with inability to rapidly modify exposures, and a reduced activity due to anti-drug antibody formation. Monoclonal antibody therapies can be challenging to manufacture in comparison to small molecule therapies. In addition, some therapies that inhibit α 4 β 7 have also interfered with α 4 β 1 integrin-ligand interactions, thereby resulting in dangerous side effects to the patient. Activity at α 4 β 1 integrin is implicated in emergence of progressive multifocal leukoencephalopathy (PML), a life-threatening and progressive brain infection, in immunosuppressed patients.

[0005] There remains a medical need for an effective and safe oral α 4 β 7 integrin inhibitor as an important addition to the therapeutic armamentarium for α 4 β 7 integrin-mediated conditions, such as inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD).SUMMARY

[0006] The invention is set out in the appended claims. In particular, the invention relates to a compound selected from the group consisting of: and or a pharmaceutically acceptable salt thereof.

[0007] The present invention also provides pharmaceutical compositions comprising any of the above compounds, or a pharmaceutically acceptable salt thereof, as the active pharmaceutical ingredient.

[0008] Furthermore, the present invention provides any of the above compounds, or a pharmaceutically acceptable salt thereof, for use as a medicament, and in particular for use in a method of treating inflammatory bowel disease, ulcerative colitis, or Crohn's disease.BRIEF DESCRIPTION OF THE FIGURES

[0009] Figure 1 is a table (Table 1) summarizing in vitro inhibition of α 4 β 7 integrin by exemplary compounds (i.e., data obtained from the fluorescence polarization assay of Example 5, and the ligand binding assay of Example 6). Figure 2 is a table (Table 2) providing additional exemplary compounds. Figure 3 is a table (Table 5) summarizing in vitro inhibition of α 4 β 7 integrin by exemplary compounds (i.e., data obtained from the fluorescence polarization assay of Example 5, and the ligand binding assay of Example 6). Figure 4 is a table (Table 6) summarizing in vitro inhibition of α 4 β 7 integrin by exemplary compounds (i.e., data obtained from the fluorescence polarization assay of Example 5, and the ligand binding assay of Example 6). DETAILED DESCRIPTION

[0010] In certain embodiments, the invention relates to compounds that antagonize α 4 β 7 integrin. The compounds will be useful for the treatment of diseases that are treatable by the inhibition of α 4 β 7 integrin (e.g., Crohn's disease (CD), and ulcerative colitis (UC)).DEFINITIONS

[0011] For convenience, before further description of the present invention, certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and understood as by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.

[0012] In order for the present invention to be more readily understood, certain terms and phrases are defined below and throughout the specification.

[0013] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0014] The phrase "and / or," as used herein in the specification and in the claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and / or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and / or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and / or B", when used in conjunction with open-ended language such as "comprising" can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

[0015] As used herein in the specification and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[0016] As used herein in the specification and in the claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently "at least one of A and / or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

[0017] It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.

[0018] In the claims, as well as in the specification above, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

[0019] Certain compounds contained in compositions of the present invention may exist in particular geometric or stereoisomeric forms. In addition, polymers of the present invention may also be optically active. The present invention contemplates all such compounds, including cisand trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.

[0020] If, for instance, a particular enantiomer of compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.

[0021] Structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds produced by the replacement of a hydrogen with deuterium or tritium, or of a carbon with a 13< C- or 14< C-enriched carbon are within the scope of this invention.

[0022] The terms "α4β7", "a4B7", "a4b7", "alpha-4 beta-7" and "alpha 4 beta 7" and the like as used herein all refer to α 4 β 7 .

[0023] The phrase "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ or portion of the body, to another organ or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, not injurious to the patient, and substantially non-pyrogenic. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations. In certain embodiments, pharmaceutical compositions of the present invention are non-pyrogenic, i.e., do not induce significant temperature elevations when administered to a patient.

[0024] The term "pharmaceutically acceptable salts" refers to the relatively non-toxic, inorganic and organic acid addition salts of the compound(s). These salts can be prepared in situ during the final isolation and purification of the compound(s), or by separately reacting a purified compound(s) in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like. (See, for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19.)

[0025] In other cases, the compounds useful in the methods of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term "pharmaceutically acceptable salts" in these instances refers to the relatively non-toxic inorganic and organic base addition salts of a compound(s). These salts can likewise be prepared in situ during the final isolation and purification of the compound(s), or by separately reacting the purified compound(s) in its free acid form with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, for example, Berge et al., supra).

[0026] A "therapeutically effective amount" (or "effective amount") of a compound with respect to use in treatment, refers to an amount of the compound in a preparation which, when administered as part of a desired dosage regimen (to a mammal, preferably a human) alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions according to clinically acceptable standards for the disorder or condition to be treated or the cosmetic purpose, e.g., at a reasonable benefit / risk ratio applicable to any medical treatment.

[0027] The term "prophylactic or therapeutic" treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, (i.e., it protects the host against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).

[0028] The term "patient" refers to a mammal in need of a particular treatment. In certain embodiments, a patient is a primate, canine, feline, or equine. In certain embodiments, a patient is a human.

[0029] An aliphatic chain comprises the classes of alkyl, alkenyl and alkynyl defined below. A straight aliphatic chain is limited to unbranched carbon chain moieties. As used herein, the term "aliphatic group" refers to a straight chain, branched-chain, or cyclic aliphatic hydrocarbon group and includes saturated and unsaturated aliphatic groups, such as an alkyl group, an alkenyl group, or an alkynyl group.

[0030] "Alkyl" refers to a fully saturated cyclic or acyclic, branched or unbranched carbon chain moiety having the number of carbon atoms specified, or 1 up to 30 carbon atoms if no specification is made. For example, alkyl of 1 to 8 carbon atoms refers to moieties such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl, and those moieties which are positional isomers of these moieties. Alkyl of 10 to 30 carbon atoms includes decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, heneicosyl, docosyl, tricosyl and tetracosyl. In certain embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C 1 -C 30 for straight chains, C 3 -C 30 for branched chains), and more preferably 20 or fewer. Alkyl goups may be substituted or unsubstituted. As used herein, "Me" and -CH 3 both refer to methyl.

[0031] As used herein, the term "alkylene" refers to an alkyl group having the specified number of carbons, for example from 2 to 12 carbon atoms, that contains two points of attachment to the rest of the compound on its longest carbon chain. Non-limiting examples of alkylene groups include methylene -(CH 2 )-, ethylene -(CH 2 CH 2 )-, n-propylene -(CH 2 CH 2 CH 2 )-, isopropylene - (CH 2 CH(CH 3 ))-, and the like. Alkylene groups can be cyclic or acyclic, branched or unbranched carbon chain moiety, and may be optionally substituted with one or more substituents.

[0032] "Cycloalkyl" means mono- or bicyclic or bridged or spirocyclic, or polycyclic saturated carbocyclic rings, each having from 3 to 12 carbon atoms. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 3-6 carbons in the ring structure. Cycloalkyl groups may be substituted or unsubstituted.

[0033] Unless the number of carbons is otherwise specified, "lower alkyl," as used herein, means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. Likewise, "lower alkenyl" and "lower alkynyl" have similar chain lengths. Throughout the application, preferred alkyl groups are lower alkyls. In certain embodiments, a substituent designated herein as alkyl is a lower alkyl.

[0034] The term "aryl" as used herein includes 3- to 12-membered substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon (i.e., carbocyclic aryl) or where one or more atoms are heteroatoms (i.e., heteroaryl). Preferably, aryl groups include 5- to 12-membered rings, more preferably 6- to 10-membered rings The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Carbocyclic aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like. Heteroaryl groups include substituted or unsubstituted aromatic 3- to 12-membered ring structures, more preferably 5- to 12-membered rings, more preferably 5- to 10-membered rings, whose ring structures include one to four heteroatoms. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Aryl and heteroaryl can be monocyclic, bicyclic, or polycyclic.

[0035] The term "halo", "halide", or "halogen" as used herein means halogen and includes, for example, and without being limited thereto, fluoro, chloro, bromo, iodo and the like, in both radioactive and non-radioactive forms. In a preferred embodiment, halo is selected from the group consisting of fluoro, chloro and bromo.

[0036] The terms "heterocyclyl" or "heterocyclic group" refer to 3- to 12-membered ring structures, more preferably 5- to 12-membered rings, more preferably 5- to 10-membered rings, whose ring structures include one to four heteroatoms. Heterocycles can be monocyclic, bicyclic, spirocyclic, or polycyclic. Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane, thiolane, oxazole, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. The heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, sulfamoyl, sulfinyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF 3 , -CN, and the like.

[0037] The term "carbonyl" is art-recognized and includes such moieties as can be represented by the formula: wherein X' is a bond or represents an oxygen or a sulfur, and R 15 represents a hydrogen, an alkyl, an alkenyl, -(CH 2 ) m -R 10 or a pharmaceutically acceptable salt, R 16 represents a hydrogen, an alkyl, an alkenyl or -(CH 2 ) m -R 10 , where m and R 10 are as defined above. Where X' is an oxygen and R 15 or R 16 is not hydrogen, the formula represents an "ester." Where X' is an oxygen, and R 15 is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R 15 is a hydrogen, the formula represents a "carboxylic acid". Where X' is an oxygen, and R 16 is a hydrogen, the formula represents a "formate." On the other hand, where X' is a bond, and R 15 is not hydrogen, the above formula represents a "ketone" group. Where X' is a bond, and R 15 is a hydrogen, the above formula represents an "aldehyde" group.

[0038] As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein above, and for example substituted with one or more substituents selected from alkyl, cycloalkyl, heterocyclylakyl, halogen, OH, OMe, C(H)F 2 , C(F)H 2 , CF 3 , C(H) 2 CF 3 , SF 5 , CHFCH 2 amine, CH 2 amine, and CN. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds. It will be understood that "substitution" or "substituted with" includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.

[0039] As used herein, the term "nitro" means -NO 2 ; the term "halogen" designates -F, -Cl, -Br, or -I; the term "hydroxyl" means -OH; and the term "cyano" means -CN;.

[0040] As used herein, the definition of each expression, e.g., alkyl, m, n, etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.

[0041] The term "prodrug" as used herein encompasses compounds that, under physiological conditions, are converted into therapeutically active agents. A common method for making a prodrug is to include selected moieties that are hydrolyzed under physiological conditions to reveal the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of the host animal.

[0042] For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover.EXEMPLARY COMPOUNDS

[0043] In some embodiments, the invention relates to a compound of Formula (I), Formula (Ia), or Formula (Ib): or a pharmaceutically acceptable salt thereof; wherein R a , R b , and R c are independently selected from the group consisting of H, Me, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CN, - OCF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 1 -C 5 )-alkoxy, -CH 2 CF 3 , and substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); provided that at least one of R a , R b , and R c is -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R 1 is substituted or unsubstituted (C 1 -C 6 )-alkyl, substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 3 -C 6 )-cycloalkyl, or substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; R 2 is R 3a and R 3b are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, -OH, -CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 , and substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; provided that R 3a and R 3b are not both H; R 3c is selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 -CN, and substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; R 3d is selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, hydroxyl, halide, and -(C 1 -C 4 )-alkoxy; R 4 is H, or substituted or unsubstituted (C 1 -C 4 )-alkyl; R 5a , and R 5e are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl hydroxyl, and (C 1 -C 4 )-alkoxy; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy.

[0044] In some embodiments, a compound of Formula (Ia) can be a compound wherein: R a is Me; R b , is substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is H; R 1 is (C 1 -C 6 )-alkyl; R 3a is halide; R 3b is (C 1 -C 5 )-alkyl; R 3c is H; R 3d is H; R 4 is H; R 5a , and R 5e are (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy, or a pharmaceutically acceptable salt thereof.

[0045] In some embodiments, a compound of Formula (Ia) can be a compound wherein: R a is Me; R b , is substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is H; R 1 is (C 1 -C 6 )-alkyl; R 3a is halide; R 3b is halide; R 3c is H; R 3d is H; R 4 is H; R 5a , and R 5e are (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy, or a pharmaceutically acceptable salt thereof.

[0046] In some embodiments, a compound of Formula (Ia) can be a compound wherein: R a is H; R b , is substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is CH(F) 2 ; R 1 is (C 1 -C 6 )-alkyl; R 3a is halide; R 3b is (C 1 -C 5 )-alkyl; R 3c is H; R 3d is H; R 4 is H; R 5a , and R 5e are (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy, or a pharmaceutically acceptable salt thereof.

[0047] In some embodiments, a compound of Formula (Ia) can be a compound wherein: R a is H; R b , is substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R e is halide; R 1 is (C 1 -C 6 )-alkyl; R 3a is halide; R 3b is (C 1 -C 5 )-alkyl; R 3c is H; R 3d is H; R 4 is H; R 5a , and R 5e are (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy, or a pharmaceutically acceptable salt thereof.

[0048] In some embodiments, a compound of Formula (Ia) can be a compound wherein: R a is CF 3 ; R b , is substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is H; R 1 is (C 1 -C 6 )-alkyl; R 3a is halide; R 38 is (C 1 -C 5 )-alkyl; R 3c is H; R 3d is H; R 4 is H; R 5a , and R 5e are (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy, or a pharmaceutically acceptable salt thereof.

[0049] In some embodiments, a compound of Formula (Ia) can be a compound wherein: R a is CF 3 ; R b , is substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is H; R 1 is (C 1 -C 6 )-alkyl; R 3a is halide; R 3b is CF 3 ; R 3c is H; R 3d is H; R 4 is H; R 5a , and R 5e are (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy, or a pharmaceutically acceptable salt thereof.

[0050] In some embodiments, a compound of Formula (Ia) can be a compound wherein: R a is CF 3 ; R b , is substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is H; R 1 is (C 1 -C 6 )-alkyl; R 3a is halide; R 3b is halide; R 3c is H; R 3d is H; R 4 is H; R 5a , and R 5e are (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy, or a pharmaceutically acceptable salt thereof.

[0051] In some embodiments, a compound of Formula (Ia) can be a compound wherein: R a is CF 3 ; R b is substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is H; R 1 is (C 1 -C 6 )-alkyl; R 3a is halide; R 3b is (C 3 -C 6 )-cycloalkyl; R 3c is H; R 3d is halide; R 4 is H; R 5a , and R 5e are (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy, or a pharmaceutically acceptable salt thereof.

[0052] In some embodiments, a compound of Formula (Ia) can be a compound wherein: R a is CF 3 ; R b is substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is H; R 1 is (C 1 -C 6 )-alkyl; R 3a is halide; R 3b is CF 3 ; R 3c is H; R 3d is halide; R 4 is H; R 5a , and R 5e are (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy, or a pharmaceutically acceptable salt thereof.

[0053] In some embodiments, a compound of Formula (Ia) can be a compound wherein: R a is CF 3 ; R b is substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is H; R 1 is (C 1 -C 6 )-alkyl; R 3a is halide; R 3b is (C 1 -C 5 )-alkyl; R 3c is H; R 3d is halide; R 4 is H; R 5a , and R 5e are (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy, or a pharmaceutically acceptable salt thereof.

[0054] In some embodiments, a compound of Formula (Ia) can be a compound wherein R 5a , is halide or (C 1 -C 5 )-alkyl; R 5b is H, halide or substituted or unsubstituted (C 1 -C 5 )-alky; R 5c is H, halide, substituted or unsubstituted (C 1 -C 5 )-alkyl, or substituted or unsubstituted (C 3 -C 6 )-cycloalkyl; and R 5d is selected from the group consisting of H, halide, CF 3 , C(H)F 2 , C(F)H 2 , - CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; and R5e is halide or or (C 1 -C 5 )-alkyl.

[0055] In some embodiments, a compound of Formula (I) can be a compound of Formula (Ia), Formula (Ib), Formula (Ic) and / or Formula (Id): wherein R a , R b , R c , R 1 , R 3a , R 3b , R 3c , R 3d , R 5a , R 5b , R 5c , R 5d , R 5e , and R 4 in Formula (Ia), Formula (Ib), Formula (Ic) and Formula (Id) are each independently defined as above with respect to Formula (I).

[0056] In some embodiments, a compound of Formula (I) can be a compound of Formula (II), including compounds of Formula (IIa), Formula (IIb) or Formula (IIc): wherein R a , R c , R 3a , R 3b , R 3c , R 3d , R 5a , R 5b , R 5c , R 5d , and R 5e , are as described in Formula (I); p is 1, 2, or 3; q is 0, 1, 2 or 3; r is an 0, 1, 2, 3 or 4; s is 0, 1, 2, 3, 4 or 5; and each R d is independently selected from the group consisting of halide, (C 1 -C 5 )-alkyl, (C 1 -C 4 )-alkoxy, -CF 3 , - C(H)F 2 , -OCF 3 , and -CN. In some embodiments, at least one instance of R d is F or Cl. In some embodiments, at least one instance of R d is methyl. In some embodiments, at least one instance of R d is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds of Formula (IIa), wherein q is 1. In certain embodiments, the invention relates to any one of the aforementioned compounds of Formula (IIb), wherein r is 1. In certain embodiments, the invention relates to any one of the aforementioned compounds of Formula (IIc), wherein s is 1.

[0057] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 1 is unsubstituted (C 1 -C 6 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 1 is substituted (C 1 -C 6 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 1 is substituted or unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, R 1 is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, sec-butyl, or t-butyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 1 is selected from the group consisting of In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 1 is substituted (C 1 -C 4 )-alkylene-(C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 1 is unsubstituted (C 1 -C 4 )-alkylene-(C 3 -C 6 )-cycloalkyl. In certain embodiments, R 1 is In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 1 is substituted (C 1 -C 4 )-alkylene- (C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 1 is unsubstituted (C I -C 4 )-alkylene- (C 1 -C 4 )-alkoxy. In certain embodiments, R 1 is . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 1 is In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 1 is

[0058] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is H; provided that R 3a and R 3b are not both H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with a halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 3a is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is substituted or unsubstituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is cyclopropyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is halide. In some embodiments, the halide is Cl or F. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is substituted -(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is unsubstituted -(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is -OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is - CH 2 OMe. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3a is F.

[0059] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is H; provided that R 3a and R 3b are not both H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with a halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 3b is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is substituted or unsubstituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is cyclopropyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is halide. In some embodiments, the halide is Cl or F. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is substituted -(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is unsubstituted -(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is -OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is - CH 2 OMe. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is selected from the group consisting of (C 1 -C 4 )-alkylene optionally substituted with one or more halide and (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is selected from the group consisting of methyl, cyclopropyl and CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is methyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is selected from the group consisting of halide, (C 1 -C 4 )-alkylene optionally substituted with one or more halide and (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is selected from the group consisting of F, Cl, methyl, and CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is methyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is F. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is Cl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3b is CF 3 .

[0060] In certain embodiments, R 3a and R 3b are independently selected from the group consisting of H, (C 1 -C 5 )-alkyl, halide, CF 3 , C(H)F 2 , and C(F)H 2 ; provided that R 3a and R 3b are not both H. For example, R 3a and R 3b can be independently selected from the group consisting of H, methyl, Cl, F, CF 3 , C(H)F 2 , and C(F)H 2 ; provided that R 3a and R 3b are not both H. In certain embodiments, R 3a is halide and R 3b is selected from the group consisting of (C 1 -C 4 )-alkylene optionally substituted with one or more halide and (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 3a is F and R 3b is selected from the group consisting of (C 1 -C 4 )-alkylene optionally substituted with one or more halide and (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 3a is F and R 3b is selected from the group consisting of methyl, cyclopropyl and CF 3 . In certain embodiments, R 3a is F and R 3b is selected from the group consisting of F, Cl, methyl, and CF 3 . In certain embodiments, R 3a is F and R 3b is selected from the group consisting of F, Cl, methyl, cyclopropyl and CF 3 .

[0061] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is selected from the group consisting of: H, substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted cyclopropyl, hydroxyl, methoxy, halide, CF 3 , C(H)F 2 , C(F)H 2 , and -CN. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with a halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 3c is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is substituted or unsubstituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is cyclopropyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is halide. In some embodiments, the halide is Cl or F. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is substituted -(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is unsubstituted -(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is -OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is -CH 2 OMe.

[0062] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is H; R 3a is halide; and R 3b is selected from the group consisting of (C 1 -C 4 )-alkylene optionally substituted with one or more halide and (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 3c is H; R 3a is F; and R 3b is selected from the group consisting of (C 1 -C 4 )-alkylene optionally substituted with one or more halide and (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 3c is H; R 3a is F; and R 3b is selected from the group consisting of methyl, cyclopropyl and CF 3 . In certain embodiments, R 3c is H; R 3a is F; R 3b is selected from the group consisting of F, Cl, methyl, and CF 3 . In certain embodiments, R 3c is H; R 3a is F; R 3b is selected from the group consisting of F, Cl, methyl, cyclopropyl and CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, hydroxyl, halide, methoxy, halide, CF 3 , C(H)F 2 , and C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with a halogen. In certain embodiments, the halogen is F. In certain embodiments, R 3d is methyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is substituted or unsubstituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is cyclopropyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is halide. In some embodiments, the halide is Cl or F In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is substituted -(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is unsubstituted -(C 1 -C 4 )-alkoxy. In certain embodiments, -(C 1 -C 4 )-alkoxy is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is -OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3d is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is -CH 2 OMe.

[0063] In some embodiments, R 3c and R 3d are the same. In some embodiments, R 3c and R 3d are both H. In some embodiments, R 3c and R 3d are different. In some embodiments, R 3c is H and R 3d is H or halide. In some embodiments, R 3c is H and R 3d is F.

[0064] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c and R 3d are both H; R 3a is halide; and R 3b is selected from the group consisting of (C 1 -C 4 )-alkylene optionally substituted with one or more halide and (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 3c and R 3d are both H; R 3a is F; and R 3b is selected from the group consisting of (C 1 -C 4 )-alkylene optionally substituted with one or more halide and (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 3c and R 3d are both H; R 3a is F; and R 3b is selected from the group consisting of methyl, cyclopropyl and CF 3 . In certain embodiments, R 3c and R 3d are both H; R 3a is F; R 3b is selected from the group consisting of F, Cl, methyl, and CF 3 . In certain embodiments, R 3c and R 3d are both H; R 3a is F; R 3b is selected from the group consisting of F, Cl, methyl, cyclopropyl and CF 3 .

[0065] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 3c is H; R 3d is F; R 3a is halide; and R 3b is selected from the group consisting of (C 1 -C 4 )-alkylene optionally substituted with one or more halide and (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 3c is H; R 3d is F; R 3a is F; and R 3b is selected from the group consisting of (C 1 -C 4 )-alkylene optionally substituted with one or more halide and (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 3c is H; R 3d is F; R 3a is F; and R 3b is selected from the group consisting of methyl, cyclopropyl and CF 3 . In certain embodiments, R 3c is H; R 3d is F; R 3a is F; R 3b is selected from the group consisting of F, Cl, methyl, and CF 3 . In certain embodiments, R 3c is H; R 3d is F; R 3a is F; R 3b is selected from the group consisting of F, Cl, methyl, cyclopropyl and CF 3 .

[0066] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 4 is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 4 is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 4 is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 4 is methyl, ethyl, n-propyl, or i-propyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 4 is methyl or ethyl.

[0067] In certain embodiments, R 5a is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is substituted or unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with one or more halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 5a is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, R 5a is methyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is halide. In some embodiments, the halide is Cl or F. In certain embodiments, R 5a is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 5a is unsubstituted (C 3 -C 6 )-cycloalkyl. In some embodiments, (C 3 -C 6 )-cycloalkyl is cyclopropyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is (C 1 -C 4 )-alkoxy. In some embodiments, (C 1 -C 4 )-alkoxy is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is hydroxyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is -OCF 3 . In certain embodiments, R 5a is CN. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is -CH 2 OMe. In certain embodiments, R 5a is CH 2 OH.

[0068] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is CN. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with a halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 5b is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, R 5a is methyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is halide. In some embodiments, the halide is Cl or F. In certain embodiments, R 5b is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 5b is unsubstituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is (C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is hydroxyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is -OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is -CH 2 OMe. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is hydrogen.

[0069] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is CN. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with a halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 5c is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, R 5c is methyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is halide. In some embodiments, the halide is Cl or F. In certain embodiments, R 5c is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 5c is cyclopropyl. In certain embodiments, R 5c is unsubstituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is (C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is hydroxyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is -OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is -CH 2 OMe. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is hydrogen.

[0070] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is CN. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with a halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 5d is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, R 5d is methyl In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is halide. In some embodiments, the halide is Cl or F. In certain embodiments, R 5d is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 5d is unsubstituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is (C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is hydroxyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is -OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is -CH 2 OMe. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is hydrogen.

[0071] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is CN. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with a halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 5e is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, R 5e is methyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is halide. In some embodiments, the halide is Cl or F. In certain embodiments, R 5e is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 5e is unsubstituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is (C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is hydroxyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is -OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is -CH 2 OMe. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is hydrogen.

[0072] In certain embodiments, R 5b is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is isubstituted or unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with one or more halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 5b is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is halide. In some embodiments, the halide is Cl or F. In certain embodiments, R 5b is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 5b is unsubstituted (C 3 -C 6 )-cycloalkyl. In some embodiments, (C 3 -C 6 )-cycloalkyl is cyclopropyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is (C 1 -C 4 )-alkoxy. In some embodiments, (C 1 -C 4 )-alkoxy is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is hydroxyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is -OCF 3 . In certain embodiments, R 5b is CN. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5b is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is - CH 2 OMe. In certain embodiments, R 5b is CH 2 OH.

[0073] In certain embodiments, R 5c is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is isubstituted or unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with one or more halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 5c is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is halide. In some embodiments, the halide is Cl or F. In certain embodiments, R 5c is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 5c is unsubstituted (C 3 -C 6 )-cycloalkyl. In some embodiments, (C 3 -C 6 )-cycloalkyl is cyclopropyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is (C 1 -C 4 )-alkoxy. In some embodiments, (C 1 -C 4 )-alkoxy is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is hydroxyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is -OCF 3 . In certain embodiments, R 5c is CN. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5a is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5c is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is - CH 2 OMe. In certain embodiments, R 5c is CH 2 OH.

[0074] In certain embodiments, R 5d is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is substituted or unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with one or more halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 5d is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is halide. In some embodiments, the halide is Cl or F. In certain embodiments, R 5d is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 5d is unsubstituted (C 3 -C 6 )-cycloalkyl. In some embodiments, (C 3 -C 6 )-cycloalkyl is cyclopropyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is (C 1 -C 4 )-alkoxy. In some embodiments, (C 1 -C 4 )-alkoxy is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is hydroxyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is -OCF 3 . In certain embodiments, R 5d is CN. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5d is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is - CH 2 OMe. In certain embodiments, R 5d is CH 2 OH.

[0075] In certain embodiments, R 5e is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is substituted or unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is substituted (C 1 -C 4 )-alkyl. In certain embodiments, the substituted (C 1 -C 5 )-alkyl, is substituted with one or more halogen. In certain embodiments, the halogen is Cl or F. In certain embodiments, R 5e is methyl, ethyl, isopropyl, n-propyl, i-butyl, n-butyl, or t-butyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is halide. In some embodiments, the halide is Cl or F. In certain embodiments, R 5e is substituted (C 3 -C 6 )-cycloalkyl. In certain embodiments, R 5e is unsubstituted (C 3 -C 6 )-cycloalkyl. In some embodiments, (C 3 -C 6 )-cycloalkyl is cyclopropyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is (C 1 -C 4 )-alkoxy. In some embodiments, (C 1 -C 4 )-alkoxy is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is hydroxyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is -OCF 3 . In certain embodiments, R 5e is CN. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is substituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R 5e is unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is - CH 2 OMe. In certain embodiments, R 5e is CH 2 OH.

[0076] In some embodiments, R 5a and R 5e are identical. For example, R 5a and R 5e can both be substituted or unsubstituted (C 1 -C 4 )-alkyl. In some examples, R 5a and R 5e are both unsubstituted (C 1 -C 4 )-alkyl (e.g., methyl). In some examples, R 5a and R 5e are both unsubstituted methyl.

[0077] In some embodiments, R 5b and R 5d are identical. For example, R 5a and R 5e can both be hydrogen.

[0078] In some embodiments, R 5a and R 5e are both substituted, and R 5b and R 5d are both hydrogen. For example, R 5a and R 5e can both be (the same or different) substituted or unsubstituted (C 1 -C 4 )-alkyl. In some examples, R 5a and R 5e can both be unsubstituted (C 1 -C 4 )-alkyl (e.g., methyl) and R 5b and R 5d are both hydrogen. In some examples, R 5a and R 5e are both unsubstituted methyl and R 5b and R 5d are both hydrogen. In some embodiments, R 5a , and R 5e are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , (C 1 -C 5 )-alkyl, hydroxyl, and (C 1 -C 4 )-alkoxy.

[0079] In some embodiments, R 5c is hydrogen, halide (e.g., F), substituted or unsubstituted (C 1 -C 4 )-alkoxy (e.g., methoxy), or substituted or unsubstituted (C 1 -C 4 )-alkyl (e.g., methyl).

[0080] In some embodiments, R 5a and R 5e are both substituted or unsubstituted (C 1 -C 5 )-alkyl, both R 5b and R 5d are hydrogen and R 5c is hydrogen, halide (e.g., F), substituted or unsubstituted (C 1 -C 4 )-alkoxy (e.g., methoxy), or substituted or unsubstituted (C 1 -C 4 )-alkyl (e.g, methyl). For example, R 5a and R 5e can both be methyl; R 5b and R 5d are both hydrogen; and R 5c is selected from the group consisting of hydrogen, halide (e.g., F), substituted or unsubstituted (C 1 -C 4 )-alkoxy (e.g., methoxy), and substituted or unsubstituted (C 1 -C 4 )-alkyl (e.g, methyl). In some examples, R 5a and R 5e can both be methyl; R 5b and R 5d are both hydrogen; and R 5c is selected from the group consisting of hydrogen, F, Cl, methoxy, and methyl. In some examples, R 5a , R 5c and R 5e are each methyl; and R 5b and R 5d are both hydrogen. In some embodiments, R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , (C 1 -C 5 )-alkyl, hydroxyl, and (C 1 -C 4 )-alkoxy.

[0081] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a , R b and R c comprise a charged amine. At least one of R a , R b and R c can be a substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); wherein R x and R y are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 6 )-alkyl, or substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; or R x and R y taken together with the N to which they are attached form a substituted or unsubstituted 4-6 membered heterocyclyl ring.

[0082] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein only one of R a , R b and R c is a substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); wherein R x and R y are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 6 )-alkyl, or substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein only one of R a , R b and R c is a substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); wherein R x and R y are independently selected from the group consisting of substituted or unsubstituted (C 1 -C 6 )-alkyl, or substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein only one of R a , R b and R c is a substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); wherein R x and R y are independently selected from the group consisting of substituted or unsubstituted (C 1 -C 6 )-alkyl.

[0083] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein only one of R a , R b and R c is a substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); wherein R x and R y taken together with the N to which they are attached form a substituted or unsubstituted 4-6 membered heterocyclyl ring. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein only one of R a , R b and R c is a substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); wherein R x and R y taken together with the N to which they are attached form a 4-6 membered heterocyclyl ring optionally substituted with one or more halide (e.g., F, Cl).

[0084] In some embodiments, R a , R b , and R c are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 4 )-alkoxy, -OCF 3 , and at least one of R a , R b , and R c is ---(C 1 -C 3 )alkylene-N-(R x )(R y ) wherein R x and R y are independently selected from the group consisting of H and (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered heterocyclyl ring optionally substituted with one or more halide (e.g., F, or Cl).

[0085] In some embodiments, R a , R b , and R c are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 4 )-alkoxy, -OCF 3 , and at least one of R a , R b , and R c is ---(C 1 -C 3 )alkylene-N-(R x )(R y ) wherein R x and R y are independently selected from the group consisting of (C 1 -C 6 )-alkyl (e.g., methyl); or R x and R y taken together with the N to which they are attached form a 4-6 membered heterocyclyl ring optionally substituted with one or more halide (e.g., F, or Cl).

[0086] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein only one of R a , R b and R c is selected from the group consisting of . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein only one of R a , R b and R c is selected from the group consisting of: In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein only one of R a , R b and R c is selected from the group consisting of:

[0087] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 4 )-alkoxy, and - OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 4 )-alkoxy, and - OCF 3 ; and one of R b and R c is a substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); wherein R x and R y are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 6 )-alkyl, or substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; or R x and R y taken together with the N to which they are attached form a substituted or unsubstituted 4-6 membered heterocyclyl ring.

[0088] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is Me. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is halide. In some embodiments, halide is Cl or F. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is substituted (C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is unsubstituted (C 1 -C 4 )-alkoxy. In some embodiments, (C 1 -C 4 )-alkoxy is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is - OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is substituted -(C 1 -C 5 )alkylene-N-(R x )(R y ). In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ). In some embodiments, -(C 1 -C 5 )alkylene of -(C 1 -C 5 )alkylene-N-(R x )(R y ) is substituted with one or more halide or -(C 1 -C 4 )alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein -(C 1 -C 5 )alkylene-N-(R x )(R y ) is - -(C 1 -C 4 )alkylene-N-(R x )(R y ).

[0089] In some embodiments, R a is substituted (C 1 -C 5 )-alkyl, substituted (C 1 -C 4 )-alkoxy, or substituted -(C 1 -C 5 )alkylene-N-(R x )(R y ), wherein substituted means substituted with halide or (C 1 -C 4 )-alkoxy. In some embodiments, R a is substituted (C 1 -C 5 )-alkyl, substituted (C 1 -C 4 )-alkoxy, or substituted -(C 1 -C 5 )alkylene-N-(R x )(R y ), wherein substituted means substituted with F or methoxy. In some embodiments, R a is selected from the group consisting of In some embodiments, In some embodiments, R a is . In some embodiments, R a is CF 3 .

[0090] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R a is selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 4 )-alkoxy, and -OCF; and R b is a substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); wherein R x and R y are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 6 )-alkyl, or substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; or R x and R y taken together with the N to which they are attached form a substituted or unsubstituted 4-6 membered heterocyclyl ring.

[0091] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is Me. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is halide. In some embodiments, halide is Cl or F. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is substituted (C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is unsubstituted (C 1 -C 4 )-alkoxy. In some embodiments, (C 1 -C 4 )-alkoxy is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is - OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is substituted -(C 1 -C 5 )alkylene-N-(R x )(R y ). In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ). In some embodiments, -(C 1 -C 5 )alkylene of -(C 1 -C 5 )alkylene-N-(R x )(R y ) is substituted with one or more halide or -(C 1 -C 4 )alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein -(C 1 -C 5 )alkylene-N-(R x )(R y ) is - -(C 1 -C 4 )alkylene-N-(R x )(R y ).

[0092] In some embodiments, R b is substituted (C 1 -C 5 )-alkyl, substituted (C 1 -C 4 )-alkoxy, or substituted -(C 1 -C 5 )alkylene-N-(R x )(R y ), wherein substituted means substituted with halide or (C 1 -C 4 )-alkoxy. In some embodiments, R b is substituted (C 1 -C 5 )-alkyl, substituted (C 1 -C 4 )-alkoxy, or substituted -(C 1 -C 5 )alkylene-N-(R x )(R y ), wherein substituted means substituted with F or methoxy. In some embodiments, R b is -(C 1 -C 5 )alkylene-N-(R x )(R y ) wherein R x and R y are each methyl, or wherein R x and R y taken together with the N to which they are attached form a 4-6 membered heterocyclyl ring optionally substituted with one or more halide (e.g., F, or Cl). In some embodiments, R b is -(C 2 -C 3 )alkylene-N-(R x )(R y ) wherein R x and R y are each methyl, or wherein R x and R y taken together with the N to which they are attached form a 4-6 membered heterocyclyl ring optionally substituted with one or more halide (e.g., F, or Cl). In some embodiments, R b is -(C 2 -C 3 )alkylene-N-(R x )(R y ) wherein R x and R y are each methyl, or wherein R x and R y taken together with the N to which they are attached form a 4-membered heterocyclyl ring optionally substituted with one or more halide (e.g., F, or Cl). In some embodiments, R b is-(C 2 -C 3 )alkylene-N-(R x )(R y ) wherein R x and R y are each methyl, or wherein R x and R y taken together with the N to which they are attached form a 4-6 membered heterocyclyl ring optionally substituted with one or more halide (e.g., F, or Cl). In some embodiments, R b is -(C 2 -C 3 )alkylene-N-(R x )(R y ) wherein R x and R y are each methyl, or wherein R x and R y taken together with the N to which they are attached form a 4-membered heterocyclyl ring optionally substituted with one or more halide (e.g., F, or Cl).

[0093] In certain embodiments, the invention relates to any one of the aforementioned compounds, R b is wherein x is 1 or 2; R 6 is H and R 6 ' is (C 1 -C 4 )alkyl optionally substituted with one or more halide (e.g., CF 3 ), or R 6 and R 6 ' together form a substituted or unsubstituted 3-6 member cycloalkyl or heterocycloalkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, R b is , wherein x is 1 or 2; R 6 is H and R 6 ' is (C 1 -C 4 )alkyl optionally substituted with one or more halide (e.g., CF 3 ), or R 6 and R 6 ' together form a 3-6 member cycloalkyl or heterocycloalkyl optionally substituted with halide (e.g., F), (C 1 -C 4 )alkyl (e.g., methyl), (C 1 -C 4 )alkoxy (e.g., methoxy), (C 3 -C 6 )cycloalkyl (e.g., spirocyclopropyl) or (C 3 -C 6 )heterocycloalkyl (e.g., azaspiro[3.3]heptyl). In some embodiments, R b is selected from the group consisting of and In some embodiments, In certain embodiments, the invention relates to any one of the aforementioned compounds, R b is selected and In some embodiments, R b is In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R b is selected from the group consisting of:

[0094] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R c is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R c is Me. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R c is halide. In some embodiments, halide is Cl or F. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R c is CF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R c is C(H)F 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R c is C(F)H 2 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R c is substituted (C 1 -C 4 )-alkoxy. In some embodiments, (C 1 -C 4 )-alkoxy is methoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R c is unsubstituted (C 1 -C 4 )-alkoxy. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R c is - OCF 3 . In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R c is substituted -(C 1 -C 5 )alkylene-N-(R x )(R y ). In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R c is unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ). In some embodiments, -(C 1 -C 5 )alkylene of -(C 1 -C 5 )alkylene-N-(R x )(R y ) is substituted with one or more halide or -(C 1 -C 4 )alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein -(C 1 -C 5 )alkylene-N-(R x )(R y ) is - -(C 1 -C 4 )alkylene-N-(R x )(R y ).

[0095] In some embodiments, R c is substituted (C 1 -C 5 )-alkyl, substituted (C 1 -C 4 )-alkoxy, or substituted -(C 1 -C 5 )alkylene-N-(R x )(R y ), wherein substituted means substituted with halide or (C 1 -C 4 )-alkoxy. In some embodiments, R c is substituted (C 1 -C 5 )-alkyl, substituted (C 1 -C 4 )-alkoxy, or substituted -(C 1 -C 5 )alkylene-N-(R x )(R y ), wherein substituted means substituted with F or methoxy.

[0096] In some embodiments, R c is selected from the group consisting of In some embodiments,

[0097] In some embodiments, at least one of R a , R b , and R c is H.

[0098] In some embodiments, at least one of R a , R b , and R c is a charged amine; and at least one of R a , R b , and R c is H.

[0099] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R x is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R x is substituted (C 1 -C 6 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R x is unsubstituted (C 1 -C 6 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R x is substituted (C 1 -C 4 )-alkyl. In some embodiments (C 1 -C 6 )-alkyl is substituted with OMe, CN, or halide. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R x is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R x is (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In some embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is -(CH 2 ) 2 OMe. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R x is Me.

[0100] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R y is H. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R y is substituted (C 1 -C 6 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R y is unsubstituted (C 1 -C 6 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R y is substituted (C 1 -C 4 )-alkyl. In some embodiments, (C 1 -C 6 )-alkyl is substituted with OMe, CN, or halide. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R y is unsubstituted (C 1 -C 4 )-alkyl. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R y is (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy. In some embodiments, (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy is -(CH 2 ) 2 OMe. In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R y is Me.

[0101] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R x is Me; and R y is Me.

[0102] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein R x and R y taken together with the N to which they are attached form a substituted or unsubstituted 4-6 membered ring. In some embodiments, the 4-6 membered ring is a substituted or unsubstituted heterocycloalkyl. In some embodiments, the substituted 4-6 membered heterocyclalkyl is substituted with halide of (C 1 -C 6 )alkyl. In some embodiments, the 4-6 membered ring is a substituted or unsubstituted heteroaryl. In some embodiments, the substituted 4-6 membered heteroaryl is substituted with halide of (C 1 -C 6 )alkyl. In some embodiments, the 4-6 membered ring is selected from In some embodiments, R x and R y taken together with the N to which they are attached form . In some embodiments, R x and R y taken together with the N to which they are attached form a substituted or unsubstituted 4-6 membered ring of the formula wherein y is 0, 1 or 2; and R 7 is H, halide, alkoxy, spirocyclic 3-5 member cycloalkyl, and spirocyclic 3-5 member heterocycloalkyl.

[0103] In some embodiments, R a is (C 1 -C 5 )-alkyl optionally substituted with halide; R b is -(C 1 -C 5 )alkylene-N-(R x )(R y ) wherein R x and R y are each methyl, or wherein R x and R y taken together with the N to which they are attached form a 4-5 membered heterocyclyl ring optionally substituted with one or more halide or alkoxy (e.g., methoxy); and R c is hydrogen, halide or (C 1 -C 5 )-alkyl optionally substituted with halide. In some embodiments, R a is methyl optionally substituted with halide; R b is -(C 2 -C 3 )alkylene-N-(R x )(R y ) wherein R x and R y are each methyl, or wherein R x and R y taken together with the N to which they are attached form a 4-5 membered heterocyclyl ring optionally substituted with one or more halide (e.g., F); and R c is hydrogen, halide or methyl optionally substituted with halide. In some embodiments, R a is methyl or CF 3 ; R b is -(C 2 -C 3 )alkylene-N-(R x )(R y ) wherein R x and R y are each methyl, or wherein R x and R y taken together with the N to which they are attached form a 4-5 membered heterocyclyl ring optionally substituted with one or more F or methoxy; and R c is hydrogen, F, CH 2 F, CHF 2 , CF 3 .

[0104] In certain embodiments, the invention relates to a compound of Formula (Ia) or (Ib): wherein R 1 , R 3c , R 3d , R 5a , R 5b , R 5c , R 5d , R 5e , R a , R b , and R c are as defined above with respect to Formula (I); R 4 is H; and at least one of R a , R b , and R c is -(C 1 -C 3 )alkylene-N(R x )(R y ); R x and R y are independently selected from the group consisting of H and methyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; and R 3a , and R 3b are each independently selected from the group consisting of methyl and F.

[0105] In certain embodiments, the invention relates to any one of the compounds depicted in Figure 1. In certain embodiments, the invention relates to any one of the compounds depicted in Figure 2. In certain embodiments, the invention relates to any one of the compounds depicted in Figure 3. In certain embodiments, the invention relates to any one of the compounds depicted in Figure 4.

[0106] In certain embodiments, a compound is a compound of Formula (I) that is not a compound depicted in Figure 1. In certain embodiments, a compound is a compound of Formula (I) that is not a compound depicted in Figure 2. In certain embodiments, a compound is a compound of Formula (I) that is not a compound depicted in Figure 3. In certain embodiments, a compound is a compound of Formula (I) that is not a compound depicted in Figure 4. In certain embodiments, a compound is a compound of Formula (I) that is not a compound depicted in Figure 2, Figure 3 or Figure 4.

[0107] In certain embodiments, the invention relates to a compound of Formula (IIIa): wherein R 1 , R a , R x , R y , R 3b , R 5b , R 5c , R 5d , are as defined above with respect to Formula (I).

[0108] In certain embodiments, the invention relates to a compound of Formula (IVa): wherein R 1 , R a , R x , R y , R 3b , R 5b , R 5c , R 5d , are as defined above with respect to Formula (I).

[0109] In certain embodiments, the invention relates to a compound selected from the group consisting of: (3S)-3-(4,5-difluoro-2',6'-dimethylbiphenyl-3-yl)-3-(2-(5-(2-(3-fluoroazetidin-1-yl)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; (3S)-3-(2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoic acid; (3S)-3-(2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; (3S)-3-(2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-3'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; (3S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-(2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; (3S)-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)-3-(2-(5-(2-(3-methoxyazetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; (3S)-3-(2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',4',5,6'-tetramethylbiphenyl-3-yl)propanoic acid; (3S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-(2-(3-(difluoromethyl)-5-(2-(dimethylamino)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; (3S)-3-(2-(5-(2-(dimethylamino)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-5-methylhexanamido)-3-(4-fluoro-2',5,6'-trimethylbiphenyl-3-yl)propanoic acid; (3S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-(2-(3-fluoro-5-(2-(3-fluoroazetidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; and (3S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-(2-(3-fluoro-5-(2-((R)-3-fluoropyrrolidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid. or a pharmaceutically acceptable salt thereof.

[0110] In certain embodiments, the invention relates to a compound selected from the group consisting of: and , or a pharmaceutically acceptable salt thereof.

[0111] In certain embodiments, the invention relates to a compound selected from the group consisting of:

[0112] In certain embodiments, the invention relates to a compound selected from the group consisting of: (S)-3-(4,5-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(3-fluoroazetidin-1-yl)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid; (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-3'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; (S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; (S)-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(3-methoxyazetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoic acid; (S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-(difluoromethyl)-5-(2-(dimethylamino)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-5-methylhexanamido)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; (S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-(3-fluoroazetidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; and (S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-((R)-3-fluoropyrrolidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; or a pharmaceutically acceptable salt thereof.

[0113] In certain embodiments, the invention relates to a compound selected from the group consisting of: and or a pharmaceutically acceptable salt thereof.

[0114] In certain embodiments, the invention relates to any one of the aforementioned compounds, wherein the compound is in the form of a pharmaceutically acceptable salt.

[0115] In certain embodiments, the invention relates to a compound selected from the group consisting of: StructureName (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(5-cyclopropyl-2,4-difluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; (3S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(5-cyclopropyl-2,3',4-trifluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoic acid (S)-3-((S)-2-(5-(3-(dimethylamino)propyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,4,4'-trifluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid (3S)-3-((S)-2-(5-(3-(dimethylamino)propyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,3',4-trifluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoic acid (3S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,4,4'-trifluoro-2',3',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid (S)-3-(2,4-difluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1, 1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,4-difluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid (S)-3-((S)-2-(5-(3-(azetidin-1-yl)propyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,4-difluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1, 1'-biphenyl]-3-yl)propanoic acid (S)-3-(2,4-difluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1, 1'-biphenyl]-3-yl)-3-((S)-2-(5-(3-(dimethylamino)propyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid (S)-3-(4'-cyclopropyl-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(3-(dimethylamino)propyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid (3S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,3',4-trifluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1, 1'-biphenyl]-3-yl)propanoic acid EXEMPLARY PHARMACEUTICAL COMPOSITIONS

[0116] Compounds of Formula (I) can be formulated in various pharmaceutical compositions. A compound of Formula (I) (including compounds of Formula (Ia) and Formula (Ib) as provided herein), as well as pharmaceutically acceptable salts thereof, may be the active pharmaceutical ingredient (API) combined with one or more other ingredients to form a drug substance pharmaceutical composition. The drug substance (DS) pharmaceutical composition can comprise the API (i.e., a compound of Formula (I) or pharmaceutically acceptable salt thereof) and one or more pharmaceutically acceptable carriers, diluents, and / or excipients. The carrier(s), diluent(s) or excipient(s) can be selected to be compatible with the other ingredients of the formulation and appropriately safe and effective for an intended therapy. A desired weight concentration of the compound of Formula (I) as the active pharmaceutical ingredient (API) can be combined with the other inactive ingredients to form a drug substance (DS) in a formulation batch. Pharmaceutically acceptable compositions can be formulated for administration by an appropriate route, for example by the oral delivery (including as a capsule or tablet) in unit dosage forms. Such compositions may be prepared by bringing into association the active pharmaceutical ingredient (API) comprising a compound of Formula (I) with the carrier(s) or excipient(s).

[0117] In certain embodiments, the invention provides a pharmaceutical composition formulated for oral delivery of an α 4 β 7 integrin integrin inhibitor, the composition comprising the α 4 β 7 integrin inhibitor compound of formula (I) as an API and a pharmaceutically acceptable carrier formulated for oral therapeutic administration of the α 4 β 7 integrin inhibitor compound.

[0118] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0119] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound of Formula (Ia), or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0120] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound of Formula (Ib), or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0121] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (3S)-3-(4,5-difluoro-2',6'-dimethylbiphenyl-3-yl)-3-(2-(5-(2-(3-fluoroazetidin-1-yl)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0122] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (3S)-3-(2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0123] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (3S)-3-(2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0124] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (3S)-3-(2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-3'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0125] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (3S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-(2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0126] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (3S)-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)-3-(2-(5-(2-(3-methoxyazetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0127] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (3S)-3-(2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',4',5,6'-tetramethylbiphenyl-3-yl)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0128] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (3S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-(2-(3-(difluoromethyl)-5-(2-(dimethylamino)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0129] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (3S)-3-(2-(5-(2-(dimethylamino)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-5-methylhexanamido)-3-(4-fluoro-2',5,6'-trimethylbiphenyl-3-yl)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0130] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (3S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-(2-(3-fluoro-5-(2-(3-fluoroazetidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0131] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (3S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-(2-(3-fluoro-5-(2-((R)-3-fluoropyrrolidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0132] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (S)-3-(4,5-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(3-fluoroazetidin-1-yl)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0133] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0134] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0135] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-3'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0136] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0137] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0138] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-(difluoromethyl)-5-(2-(dimethylamino)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0139] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-5-methylhexanamido)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0140] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-(3-fluoroazetidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0141] In certain embodiments, the invention provides a pharmaceutical composition comprising the compound (S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-((R)-3-fluoropyrrolidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient (API).

[0142] In certain embodiments, the invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of: and or a pharmaceutically acceptable salt thereof.

[0143] In certain embodiments, the invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of, or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingrediend (API): StructureName (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(5-cyclopropyl-2,4-difluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; (3S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(5-cyclopropyl-2,3',4-trifluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoic acid (S)-3-((S)-2-(5-(3-(dimethylamino)propyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,4,4'-trifluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid (3S)-3-((S)-2-(5-(3-(dimethylamino)propyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,3',4-trifluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoic acid (3S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,4,4'-trifluoro-2',3',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid (S)-3-(2,4-difluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1, 1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,4-difluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1, 1'-biphenyl]-3-yl)propanoic acid (S)-3-((S)-2-(5-(3-(azetidin-1-yl)propyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,4-difluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid (S)-3-(2,4-difluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1, 1'-biphenyl]-3-yl)-3-((S)-2-(5-(3-(dimethylamino)propyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid (S)-3-(4'-cyclopropyl-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(3-(dimethylamino)propyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid (3S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2,3',4-trifluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1, 1'-biphenyl]-3-yl)propanoic acid.

[0144] Pharmaceutically acceptable compositions comprising the compound of Formula (I) can be prepared by various procedures. For example, the compounds of Formula (I) can be formulated with suitable excipients, diluents, or carriers, and formed into tablets, or capsules, and other suitable dosage forms.

[0145] Pharmaceutical compositions can be provided in unit dose forms containing a predetermined amount of API comprising a compound of Formula (I) per unit dose. Such a unit may contain, a desired amount of a compound of the Formula (I) or pharmaceutically acceptable salt thereof, depending on the condition being treated, the route of administration and the age, weight and condition of the patient. Such unit doses may therefore be administered at a desired dose interval. The concentration of active compound in the drug composition will depend on various applicable parameters and considerations such as the absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient can be administered at once, or can be divided into a number of smaller doses to be administered at varying intervals of time.

[0146] In certain embodiments, the mode of administration of the active compound is oral. Oral compositions will generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and / or adjuvant materials can be included as part of the composition. Pharmaceutical compositions comprising a compound of Formula (I) formulated for oral delivery can be prepared in a unit dosage form, such as a capsule at a desired dosage strength of the compound of Formula (I). For oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. For oral administration in the form of a tablet or capsule, the compound of Formula (I) can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier. Other examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, and sugars; and binding agents such as cellulose derivatives. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, natural sugars, natural and synthetic gums, and the like. Lubricants and / or glidants can be used in these dosage forms.

[0147] The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, unit dosage forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, or other enteric agents.

[0148] The compound can be administered as a component of an elixir, suspension, syrup, wafer, or the like. A syrup can contain, in addition to the active compound(s), sucrose or sweetener as a sweetening agent and certain preservatives, dyes and colorings and flavors.

[0149] The compounds can be formulated as solutions appropriate for parenteral administration, for example, by intramuscular, subcutaneous or intravenous routes. For example, a compound of Formula (I) can be dissolved in a suitable buffer. A pharmaceutical composition comprising a desired concentration of a compound of Formula (I) can be formulated as an injectable drug solution in (useful, e.g., in preclinical animal studies).EXEMPLARY METHODS

[0150] Compounds inhibiting α 4 β 7 are useful for development of medicaments to treat ulcerative colitis and Crohn's disease patients. Ulcerative colitis (UC) and Crohn's disease (CD) patients suffer from autoimmune inflammation in the digestive tract and for many of these patients, the CD4 +< memory T cells drive the progression and flare ups of the disease via their ability to secrete pro-inflammatory, effector cytokines within the gut, impacting the surrounding immune cells and tissue. The progression and flare ups of these disease conditions are believed to include extravasation of T cells leaving the blood to enter tissue in the gut leading to inflammatory conditions found in UC and CD via integrin related mechanisms. The inhibition of α 4 β 7 can disrupt this mechanism, thereby preventing the localization of T cells to the tissue and effectively treating and preventing disease such as UC and CD. T cell homing to the gut requires surface expression of integrin α 4 β 7 and chemokine receptor CCR9. While CCR9 is utilized by the cell to migrate against the gradient of CCL25 expressed in the small intestine, α 4 β 7 is a tethering molecule which binds the ligand, mucosal addressin cell adhesion molecule 1 (MAdCAM-1). Integrin α 4 β 7 binds MAdCAM-1 with high affinity facilitating rolling and firm adhesion of cells followed by extravasation into tissue.

[0151] Pharmaceutical compositions can comprise compounds that inhibit the α 4 β 7 integrin on inflammatory cells that enables adhesion of these cells to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), and inhibiting or preventing these cells from entering the gut lamina propria and gut associated lymphoid tissue.

[0152] Compounds of Formula (I) were evaluated using a fluorescent polarization (FP) assay, as described in Example 5. FP assays are used to evaluate potency of compounds on purified protein. The FP assays consists of measuring purified integrin αβ heterodimer ecto domains or headpiece binding to surrogate or truncated ligands. Results of the FP assay for exemplary compounds of Formula (I) are provided herein.

[0153] Compounds of Formula (I) were further evaluated using a Ligand binding assay (LBA) as described in Example 6 to examine compound potency of free ligand binding to receptors expressed on cells. The MAdCAM ligand binding assay uses flow cytometry to measure the binding of fluorescently-labeled MAdCAM-1-Fc to RPMI 8866 cells in the presence of Mn++. This assay assesses the binding of compounds to native full-length receptors on the cell surface. One advantage of the MAdCAM ligand binding assay is its ability to quantify and discriminate the activity of potent compounds that exceed the FP assay's functional sensitivity limit [~10nM in Mn]. Ligand binding assays (LBA) are used to examine compound potency and selectivity of free ligand binding to receptors expressed on cells.

[0154] In some embodiments, compounds of the invention can be a compound of Formula (I): wherein R a , R b , and R c are independently selected from the group consisting of H, Me, halide, CF 3 , C(H)F 2 , C(F)H 2 , and -(C 1 -C 5 )alkylene-N-(R x )(R y ); provided that at least one of R a , R b , and R c is -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R 1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, or t-butyl; R 2 is R 3a and R 3b are independently selected from the group consisting of halide, substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted (C 1 -C 4 )-alkoxy, CF 3 , C(H)F 2 , and C(F)H 2 ; R 3c , and R 3d are H; R 4 is H; R 5a is methyl; R 5b is selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; R 5c is methyl; R 5d is H; R 5e is selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted (C 1 -C 5 )-alkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; or a pharmaceutically acceptable salt thereof.

[0155] In some embodiments, compounds of the invention can be a compound of Formula (Ia): wherein R a , R b , and R c are independently selected from the group consisting of H, Me, halide, CF 3 , C(H)F 2 , C(F)H 2 , and -(C 1 -C 5 )alkylene-N-(R x )(R y ); provided that at least one of R a , R b , and R c is -(C 1 -C 5 )alkylene-N-(R x )(R y ); at least one of R a , R b , and R c is -(C 1 -C 3 )alkylene-N(R x )(R y ); R x and R y are independently selected from the group consisting of H and methyl; or R x and R y taken together with the N to which they are attached form a substituted or unsubstituted 4-6 membered ring ; R 1 is substituted or unsubstituted (C 1 -C 6 )-alkyl, substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 3 -C 6 )-cycloalkyl, or substituted or unsubstituted (C 1 -C 4 )-alkylene- (C 1 -C 4 )-alkoxy; R 2 is R 3a , and R 3b are each independently selected from the group consisting of methyl and F, and R 3a is halide; R 3c , and R 3d are H; R 4 is H, or substituted or unsubstituted (C 1 -C 4 )-alkyl; R 5a is selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted (C 1 -C 5 )-alkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; and R 5b , and R 5c are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; and R 5d is H; R 5e is methyl; or a pharmaceutically acceptable salt thereof.

[0156] In some embodiments, compounds of the invention can be a compound of Formula (Ic) wherein R a , R b , and R c are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 4 )-alkoxy, -OCF 3 , and substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); provided that one of R a , R b , and R c is -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 6 )-alkyl, or substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; or R x and R y taken together with the N to which they are attached form a substituted or unsubstituted 4-6 membered heterocyclyl ring; R 3a is halide and R 3b is selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, -OH, -CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 , and substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; R 3c is H, substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 -CN, and substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; R 3d is selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, hydroxyl, halide, and -(C 1 -C 4 )-alkoxy; R 5a , and R 5e are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 5 )-alkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 5 )-alkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; or a pharmaceutically acceptable salt thereof.

[0157] In some embodiments, compounds of the invention can be a compound (3S)-3-(2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(2-fluoro-3-methyl-5-((S)-2-methylpiperidin-1-yl)phenyl)propanoic acid or a pharmaceutically acceptable salt thereof.

[0158] In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the subject is a mammal. In certain embodiments, the invention relates to any one of the aforementioned methods, wherein the subject is human.EXAMPLES

[0159] The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.

[0160] Examples 1-4 describe the synthesis of certain compounds presented in Figure 1, including compounds of Formula (Ia) and Formula (Ib). Compounds in Figure 1 can be prepared as a mixture of diastereomeric compounds (e.g., as disclosed in Examples 1-4) having a (3S) configuration (i.e., at the stereocenter beta to the carboxylic acid moiety), and a mixture of diastereomers at the chiral center covalently bound to the pyridone ring nitrogen atom of Formula (I) (e.g., as shown in Formula (Ib)).

[0161] In Figure 1, compounds having greater activity in the fluorescence polarization (FP) assay of Example 5 are shown with the stereochemistry of Formula (Ia). Example 5 describes a fluorescence polarization (FP) assay. Example 6 describes a ligand binding (LB) assay. Example 7 describes a cell adhesion (CA) assay.

[0162] In some embodiments, the following compound of Formula (I): wherein R a , R b , and R c are independently selected from the group consisting of H, Me, halide, CF 3 , C(H)F 2 , C(F)H 2 , and -(C 1 -C 5 )alkylene-N-(R x )(R y ); provided that at least one of R a , R b , and R c is -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R 1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, or t-butyl; R 2 is R 3a and R 3b are independently selected from the group consisting of H, (C 1 -C 5 )-alkyl, (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, -OH, -CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 , and substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; provided that R 3a and R 3b are not both H; R 3c , and R 3d are H; R 4 is H; R 5a , and R 5e are independently methyl; R 5b , and R 5c are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; R 5d is H; and wherein the compound of Formula (I) is selected from the group consisting of: a. (S)-3-(4,5-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(3-fluoroazetidin-1-yl)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; b. (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid; c. (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; d. (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-3'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; e. (S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; f. (S)-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(3-methoxyazetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; g. (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoic acid; h. (S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-(difluoromethyl)-5-(2-(dimethylamino)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; i. (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-5-methylhexanamido)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; j. (S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-(3-fluoroazetidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; and k. (S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-((R)-3-fluoropyrrolidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; or a pharmaceutically acceptable salt thereof.

[0163] In some embodiments, wherein the compound is (S)-3-(4,5-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(3-fluoroazetidin-1-yl)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid, or a pharmaceutically acceptable salt thereof.

[0164] In some embodiments, wherein the compound is (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid, or a pharmaceutically acceptable salt thereof.

[0165] In some embodiments, wherein the compound is (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid, or a pharmaceutically acceptable salt thereof.

[0166] In some embodiments, wherein the compound is (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-3'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid, or a pharmaceutically acceptable salt thereof.

[0167] In some embodiments, wherein the compound is (S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid, or a pharmaceutically acceptable salt thereof.

[0168] In some embodiments, wherein the compound is (S)-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(3-methoxyazetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid, or a pharmaceutically acceptable salt thereof.

[0169] In some embodiments, wherein the compound is (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoic acid, or a pharmaceutically acceptable salt thereof.

[0170] In some embodiments, wherein the compound is (S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-(difluoromethyl)-5-(2-(dimethylamino)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid, or a pharmaceutically acceptable salt thereof.

[0171] In some embodiments, wherein the compound is (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-5-methylhexanamido)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid, or a pharmaceutically acceptable salt thereof.

[0172] In some embodiments, wherein the compound is (S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-(3-fluoroazetidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid, or a pharmaceutically acceptable salt thereof.

[0173] In some embodiments, wherein the compound is (S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-((R)-3-fluoropyrrolidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid, or a pharmaceutically acceptable salt thereof.

[0174] In some embodiments, a pharmaceutical composition comprising a compound of Formula (I) as the active pharmaceutical ingredient: wherein R a , R b , and R c are independently selected from the group consisting of H, Me, halide, CF 3 , C(H)F 2 , C(F)H 2 , and -(C 1 -C 5 )alkylene-N-(R x )(R y ); provided that at least one of R a , R b , and R c is -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R 1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, or t-butyl; R 2 is R 3a and R 3b are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, -OH, -CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 , and substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; provided that R 3a and R 3b are not both H; R 3c , and R 3d are H; R 4 is H; R 5a , and R 5e are independently methyl; R 5b , and R 5c are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; R 5d is H; and wherein the compound of Formula (I) is selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

[0175] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0176] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0177] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0178] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0179] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0180] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0181] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0182] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0183] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0184] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0185] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0186] In some embodiments, a compound of Formula (Ia): wherein: R a , is CF 3 ; R b is substituted or unsubstituted -(C 1- C 5 )alkylene-N-(R x )(R y ); R x and R y are independently substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is H; R 1 is substituted or unsubstituted (C 1 -C 6 )-alkyl; R 2 is R 3a and R 3b are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, -OH, -CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 , and substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; provided that R 3a and R 3b are not both H; R 3c is H; R 3d is halide; R 4 is H; R 5a , and R 5e are each independently selected from (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; wherein the compound of Formula (I) is selected from the group consisting of:

[0187] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0188] In some embodiments,, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0189] In some embodiments,, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0190] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0191] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0192] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0193] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0194] The compound of claim 25, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0195] The compound of claim 25, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0196] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0197] In some embodiments, wherein the compound is or a pharmaceutically acceptable salt thereof.

[0198] In some embodiments, a pharmaceutical composition comprising a compound of the present application or a pharmaceutically acceptable salt thereof as the active pharmaceutical ingredient. In some embodiments, the the invention relates to a compound of Formula (I), Formula (Ia), or Formula (Ib): or a pharmaceutically acceptable salt thereof; wherein R a , R b , and R c are independently selected from the group consisting of H, Me, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CN, - OCF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, (C 1 -C 5 )-alkoxy,-CH 2 CF 3 , and substituted or unsubstituted -(C 1- C 5 )alkylene-N-(R x )(R y ); provided that at least one of R a , R b , and R c is -(C 1 -C 5 )alkylene-N-(R x )(R y ), wherein the substituted (C 1 -C 5 )-alkyl is substituted with halide, amino, or (C 1 -C 4 )-alkylamino; and the substituted -(C 1 -C 5 )alkylene-N-(R x )(R y ) is substituted with halide or (C 1 -C 4 )-alkoxy; R x and R y are independently selected from the group consisting of H and (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R 1 is (C 1 -C 6 )-alkyl, (C 1 -C 4 )-alkylene-(C 3 -C 6 )-cycloalkyl, or (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; R 2 is R 3a and R 3b are independently selected from the group consisting of H, (C 1 -C 5 )-alkyl, (C 3 -C 6 )-cycloalkyl, 3-6 membered heterocycloalkyl, -OH, -CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , - (C 1 -C 4 )-alkoxy, -OCF 3 , and (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; provided that R 3a and R 3b are not both H; R 3c is selected from the group consisting of H, (C 1 -C 5 )-alkyl, (C 3 -C 6 )-cycloalkyl, 3-6 membered heterocycloalkyl, hydroxyl, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 -CN, and (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; R 3d is selected from the group consisting of H, (C 1 -C 5 )-alkyl, hydroxyl, halide, and -(C 1 -C 4 )-alkoxy; R 4 is H, or (C 1 -C 4 )-alkyl; R 5a , and R 5e are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , (C 3 -C 6 )-cycloalkyl, (C 1 -C 5 )-alkyl, 3-6 membered heterocycloalkyl hydroxyl, and (C 1 -C 4 )-alkoxy; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , (C 1 -C 5 )-alkyl, (C 3 -C 6 )-cycloalkyl, 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy.

[0199] In one embodiment of the above Formula (Ib), the compound is not a compound recited in Figure 1.

[0200] In one embodiment of the above Formula (Ib), the compound is a compound recited in Figure 2 and / or 3.

[0201] In some embodiments, the the invention relates to a compound of Formula (I), Formula (Ia), or Formula (Ib): or a pharmaceutically acceptable salt thereof; wherein R a , R b , and R c are independently selected from the group consisting of H, Me, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CN, - OCF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, (C 1 -C 5 )-alkoxy,-CH 2 CF 3 , and substituted or unsubstituted -(C 1- C 5 )alkylene-N-(R x )(R y ); provided that at least one of R a , R b , and R c is -(C 1 -C 5 )alkylene-N-(R x )(R y ), wherein the substituted (C 1 -C 5 )-alkyl is substituted with halide, amino, or (C 1 -C 4 )-alkylamino; and the substituted -(C 1 -C 5 )alkylene-N-(R x )(R y ) is substituted with halide, (C 1 -C 5 )-alkyl, (C 1 -C 5 )-alkyl-OCH 3 , (C 1 -C 4 )-haloalkyl, (C 3 -C 6 )-cycloalkyl,(C 1 -C 4 )-alkoxy, or heterocyclyl; R x and R y are independently selected from the group consisting of H and (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R 1 is substituted or unsubstituted (C 1 -C 6 )-alkyl, (C 1 -C 4 )-alkylene-(C 3 -C 6 )-cycloalkyl, or (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy, wherein the substituted (C 1 -C 6 )-alkyl is substituted with halide or (C 3 -C 6 )-cycloalkyl; R 2 is R 3a and R 3b are independently selected from the group consisting (C 1 -C 5 )-alkyl, (C 3 -C 6 )-cycloalkyl, 3-6 membered heterocycloalkyl, -OH, -CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 , and (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; provided that R 3a and R 3b are not both H; R 3c is selected from the group consisting of H, (C 1 -C 5 )-alkyl, (C 3 -C 6 )-cycloalkyl, 3-6 membered heterocycloalkyl, hydroxyl, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 -CN, and substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; R 3d is selected from the group consisting of H, (C 1 -C 5 )-alkyl, hydroxyl, halide, and -(C 1 -C 4 )-alkoxy; R 4 is H, or (C 1 -C 4 )-alkyl; R 5a , and R 5e are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , (C 3 -C 6 )-cycloalkyl (C 1 -C 5 )-alkyl, 3-6 membered heterocycloalkyl hydroxyl, and (C 1 -C 4 )-alkoxy; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , (C 1 -C 5 )-alkyl, (C 3 -C 6 )-cycloalkyl, 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy.

[0202] In one embodiment of the above Formula (Ib), the compound is not a compound recited in Figure 1.

[0203] In one embodiment of the above Formula (Ib), the compound is a compound recited in Figure 2 and / or 3.

[0204] In some embodiments, a compound of Formula (I) can be a compound of Formula (Ib), wherein R a is selected from the group consisting of hydrogen, and (C 1 -C 5 )-alkyl optionally substituted with halide; R b is -(C 1- C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring optionally substituted with halide or (C 1 -C 4 )-alkoxy; R c are is selected from the group consisting of hydrogen and (C 1 -C 5 )-alkyl optionally substituted with halide; R 1 is (C 1 -C 6 )-alkyl; R 3a is halide; R 3b is selected from the group consisting of (C 1 -C 5 )-alkyl optionally substituted with halide, and (C 3 -C 6 )-cycloalkyl; R 3c is hydrogen; R 3d is selected from the group consisting of H and halide; R 4 is hydrogen; R 5a , and R 5e are each (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, (C 1 -C 5 )-alkyl optionally substituted with halide (e.g., CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 ), (C 3 -C 6 )-cycloalkyl, 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy.

[0205] In some embodiments, a compound of Formula (I) can be a compound of Formula (Ia), wherein R a is selected from the group consisting of hydrogen, and methyl optionally substituted with halide; R b is -(C 1- C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of methyl and ethyl; or R x and R y taken together with the N to which they are attached form a 4-5 membered ring optionally substituted with F or methoxy; R c are is selected from the group consisting of hydrogen and methyl optionally substituted with halide; R 1 is selected from the group consisting of isobutyl and isopentyl; R 3a is F; R 3b is selected from the group consisting of (C 1 -C 5 )-alkyl optionally substituted with F, and (C 3 -C 6 )-cycloalkyl; R 3c is hydrogen; R 3d is selected from the group consisting of H and F; R 4 is hydrogen; R 5a , and R 5e are each methyl; R 5b and R 5d are independently selected from the group consisting of H, F, methyl and methoxy; and R 5c is selected from the group consisting of F, methyl and cyclopropyl.

[0206] In some embodiments, a compound of Formula (I) can be a compound of Formula (Ia), wherein R a is selected from the group consisting of hydrogen, and methyl optionally substituted with halide; R b is -(C 1- C 5 )alkylene-N-(R x )(R y ); R x and R y are methyl; or R x and R y taken together with the N to which they are attached form a 4-5 membered ring optionally substituted with F or methoxy; R c are is selected from the group consisting of hydrogen and methyl optionally substituted with halide; R 1 is selected from the group consisting of isobutyl and isopentyl; R 3a is F; R 3b is selected from the group consisting of (C 1 -C 5 )-alkyl optionally substituted with F, and (C 3 -C 6 )-cycloalkyl; R 3c is hydrogen; R 3d is F; R 4 is hydrogen; R 5a , and R 5e are each methyl; R 5b and R 5d are independently selected from the group consisting of H, F, methyl and methoxy; and R 5c is selected from the group consisting of F, methyl and cyclopropyl.

[0207] In some embodiments, a compound of Formula (I) can be a compound of Formula (Ia): or a pharmaceutically acceptable salt thereof, wherein R a , R b , R c , R 1 , R 3a , R 3b , R 3c , R 3d , R 5a , R 5b , R 5c , R 5d , R 5e , and R 4 in Formula (Ia) are each independently defined as above with respect to Formula (I), and provided that the compound of Formula (Ia) is not a compound selected from the group consisting of:

[0208] In some embodiments, a compound of Formula (I) can be a compound of Formula (Ib): or a pharmaceutically acceptable salt thereof, wherein R a , R b , R c , R 1 , R 3a , R 3b , R 3c , R 3d , R 5a , R 5b , R 5c , R 5d , R 5e , and R 4 in Formula (Ia) are each independently defined as above with respect to Formula (I), and provided that the compound of Formula (Ia) is not a compound selected from the group consisting of:

[0209] In some embodiments, a compound can be a compound of Formula (I) wherein R a , R b , and R c are independently selected from the group consisting of H, Me, halide, CF 3 , C(H)F 2 , C(F)H 2 , and -(C 1 -C 5 )alkylene-N-(R x )(R y ); provided that at least one of R a , R b , and R c is -(C 1- C 5 )alkylene-N-(R x )(R y ); R x and R y are independently selected from the group consisting of H and substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R 1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, or t-butyl; R 2 is R 3a and R 3b are independently selected from the group consisting of H, (C 1 -C 5 )-alkyl, (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, -OH, -CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 , and substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; provided that R 3a and R 3b are not both H; R 3c , and R 3d are H; R 4 is H; R 5a , and R 5e are independently methyl; R 5b , and R 5c are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; R 5d is H; and provided the compound of Formula (I) is not a compound selected from the group consisting of: a. (S)-3-(4,5-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(3-fluoroazetidin-1-yl)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; b. (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid; c. (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; d. (S)-3-((S)-2-(5-(2-(azetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-3'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; e. (S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; f. (S)-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(5-(2-(3-methoxyazetidin-1-yl)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; g. (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-2-oxo-4-(trifluoromethyl)pyridin-1(2H)-yl)-4-methylpentanamido)-3-(4-fluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoic acid; h. (S)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-(difluoromethyl)-5-(2-(dimethylamino)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; i. (S)-3-((S)-2-(5-(2-(dimethylamino)ethyl)-4-methyl-2-oxopyridin-1(2H)-yl)-5-methylhexanamido)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoic acid; j. (S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-(3-fluoroazetidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; and k. (S)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)-3-((S)-2-(3-fluoro-5-(2-((R)-3-fluoropyrrolidin-1-yl)ethyl)-2-oxopyridin-1(2H)-yl)-4-methylpentanamido)propanoic acid; or a pharmaceutically acceptable salt thereof.

[0210] In some embodiments, a compound can be a compound of Formula (Ia) wherein: R a , is CF 3 ; R b is substituted or unsubstituted -(C 1- C 5 )alkylene-N-(R x )(R y ); R x and R y are independently substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is H; R 1 is substituted or unsubstituted (C 1 -C 6 )-alkyl; R 3a and R 3b are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, -OH, -CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 , and substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; provided that R 3a and R 3b are not both H; R 3c is H; R 3d is halide; R 4 is H; R 5a , and R 5e are each independently selected from (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; or a pharmaceutically acceptable salt thereof; provided the compound of Formula (Ia) is not selected from the group consisting of:

[0211] In some embodiments, a compound can be a compound of Formula (Ib) wherein: R a , is CF 3 ; R b is substituted or unsubstituted -(C 1 -C 5 )alkylene-N-(R x )(R y ); R x and R y are independently substituted or unsubstituted (C 1 -C 6 )-alkyl; or R x and R y taken together with the N to which they are attached form a 4-6 membered ring; R c is H; R 1 is substituted or unsubstituted (C 1 -C 6 )-alkyl; R 3a and R 3b are independently selected from the group consisting of H, substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, -OH, -CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -(C 1 -C 4 )-alkoxy, -OCF 3 , and substituted or unsubstituted (C 1 -C 4 )-alkylene-(C 1 -C 4 )-alkoxy; provided that R 3a and R 3b are not both H; R 3c is H; R 3d is halide; R 4 is H; R 5a , and R 5e are each independently selected from (C 1 -C 5 )-alkyl; and R 5b , R 5c , and R 5d are independently selected from the group consisting of H, CN, halide, CF 3 , C(H)F 2 , C(F)H 2 , -CH 2 CF 3 , substituted or unsubstituted (C 1 -C 5 )-alkyl, substituted or unsubstituted (C 3 -C 6 )-cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, hydroxyl, and (C 1 -C 4 )-alkoxy; or a pharmaceutically acceptable salt thereof; provided the compound of Formula (Ib) is not selected from the group consisting of: Example 1. General Schemes for the synthesis of α4β7 inhibitors β-amino acid synthesis

[0212] The synthesis of β-amino acids can be achieved using well known procedures described in the literature, such as but not limited to "Enantioselective Synthesis of β-Amino Acids," Second Edition, Editors: Eusebio Juaristi, Vadim A. Soloshonok, First published:27 January 2005, John Wiley & Sons, Inc.; Ellman et. Al Acc. Chem. Res.2002. 35, 984-995; Franklin A.

[0213] Davis and Bang-Chi Chen Chem. Soc. Rev., 1998, 27, 13-18; Jacobsen, M. F.; Skrydstrup, T. J. Org. Chem. 2003, 68, 7122; Tang, T. P.; Ellman, J. A. J. Org. Chem. 2002, 67, 7819 ;and Tang, T. P.; Ellman, J. A. J. Org. Chem. 1999, 64, 12.Reductive Aminations

[0214]

[0215] Procedure A: A mixture of amine (1 equiv.), aldehyde (1.2 equiv.) in DCM (1-2 mL / mmol amine) was stirred at room temperature for 30 min. Then NaBH(OAc) 3 (1.5 equiv.) was added portion-wise and stirred at room temperature overnight. The solvent was concentrated in vacuo and the residue was purified by silica gel chromatography to provide the desired amine.

[0216] Procedure B: A mixture of aldehyde (1 equiv.), amine (1.05-2 equiv.) in DCE (3-4 mL / mmol of aldehyde) was stirred at room temperature for 10-30 mins. Then NaBH(OAc) 3 (3-4 equiv.) was added portion-wise and stirred at room temperature 1-16 until complete by LC / MS. The solvent was concentrated in vacuo and the residue was purified by silica gel chromatography to provide the desired amine.

[0217] Procedure C: A mixture of aldehyde (1 equiv.), AcOH (1.2 equiv), amine (1.05-2 equiv.) in DCM (2-3 mL / mmol aldehyde) and MeOH (0.5 mL / mmol aldehyde) was stirred at room temperature for 15-30 mins Then NaBH(OAc) 3 (2 equiv.) was added portion-wise and stirred at room temperature 1-16 until complete by LC / MS. The solvent was concentrated in vacuo and the residue was purified by silica gel chromatography to provide the desired amine.Alkylations

[0218]

[0219] Procedure A: To a solution of amine (1 equiv.) in MeCN (3-4 mL / mmol amine) was added mesylate (1.5 equiv.) and K 2 CO 3 (3 equiv.). The reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC to give the alkylated product.

[0220] Procedure B: To a solution of amine (1 equiv.) in MeCN (3-4 mL / mmol amine) was added alkylbromide (2 equiv.) and K 2 CO 3 (2 equiv.). The reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC to give the alkylated product.Phenol Deprotections

[0221]

[0222] A mixture of methoxypyridine (1 equiv.) in 44% HBr / AcOH (10 mL / mmol of substrate) was heated at 55-75°C for 5-16 hours until complete by LCMS. The reaction was concentrated in vacuo and the residue purified by reverse phase HPLC to give the phenol product.Wittig Reactions

[0223]

[0224] Procedure A: A mixture of (methoxymethyl)triphenylphosphonium chloride (1.5 equiv.), t-BuOK (2.5 equiv.) in dioxane (2 mL / mmol phosphonium salt) was stirred at room temperature for 15 minutes. Then aldehyde (1 equiv.) in THF (1 mL / mmol aldehyde) was added. The mixture was stirred for 2-16 h at room temperature. The reaction mixture was worked up (diluted with water and extracted with EtOAc; combined extacts dried over Na 2 SO 4 , filtered and concentrated) and purified by silica gel chromatography to give the enol ether product.

[0225] Procedure B: A mixture of (methoxymethyl)triphenylphosphonium chloride (1.1equiv.), t-BuOK (2.5 equiv.) in THF (4 mL / mmol phosphonium salt) was stirred at 0°C for 1 h. Then aldehyde (1 equiv.) in THF (2 mL / mmol aldehyde) was added. The mixture was stirred for 16 h at room temperature. The reaction mixture was worked up (diluted with water and extracted with EtOAc; combined extacts dried over Na 2 SO 4 , filtered, and concentrated) and purified by silica gel chromatography to give the enol ether product.Enol Ether to Aldehyde

[0226]

[0227] Procedure A: Enol ether (1 equiv.) was treated with TFA (2 mL / mmol) at room temperature for 4 hours. The solvent was removed in vacuo to provide the desired aldehyde.

[0228] Procedure B: Enol ether (1 equiv.) was treated with HCOOH (2 mL / mmol) at 70°C for 2 hours. The solvent was removed in vacuo to provide the desired aldehyde.

[0229] Procedure C: To a solution of enol ether (1 equiv.) in DCM (15 mL / mmol enol ether) was added TFA (2 mL / mmol) and water (0.25 mL / mmol enol ether). The reaction was stirred at 45°C for 18 h. The reaction was worked up (quenched with NaHCO 3 , extracted with DCM; combined extracts dried over Na 2 SO 4 , filtered, and concentrated) to provide the desired aldehyde.Stille Reaction

[0230]

[0231] To a solution of arylbromide (1 equiv.) and allylstannane (1.2 equiv.) under N 2 in DMF (3 mL / mmol arylbromide) was added Pd(PPh 3 ) 4 (0.1 equiv.). The reaction was stirred at 100°C for 16 hours. The reaction was concentration in vacuo then diluted with EtOAc, poured into 20% aq. KF and stirred for 1 h and extracted. The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated, and purified by silica gel chromatography to provide the desired product.Alkene to Aldehyde

[0232]

[0233] To a solution of alkene (1 equiv.) in THF / H 2 O (1:1) (10 mL / mmol of alkene) at 0°C was added K 2 OsO 4 -2H 2 O (0.01 equiv.). The mixture was stirred at 0°C for 5 min then NaIO 4 (3 equiv.) in H 2 O (1 mL / mmol alkene) was added dropwise and stirred at 0°C for 1 h then warmed to room temperature and stirred until complete by LCMS. The reaction was worked up (dilute with water and extract with EtOAc; combined organic layers were dried over Na 2 SO 4 , filtered, and concentrated) to give the desired aldehyde.Ester to Acid

[0234]

[0235] The ester (1 equiv.) was treated with LiOH-H 2 O (3-5 equiv.) in MeOH (1-3 mL / mmol ester) and water (1-3 mL / mmol ester) at room temperature for 1-5 h. The reaction was acidified with 1N HCl to pH=3 and concentrated. The residue was purified by prep HPLC to give the desired carboxylic acid product.Amine protection

[0236]

[0237] A mixture of amine (1 equiv.), DIEA (3 equiv.), and Boc 2 O (2 equiv.) was stirred in DCM (5 mL / mmole amine) at room temperature for 16 h until complete by LCMS. The reaction was worked up (wash with 0.5 N HCl, sat. NaHCO 3 , brine, extract with DCM; combined organic layers were dried over Na 2 SO 4 , filtered, and concentrated) and purified by silica gel chromatography.Preparation of arylborane

[0238]

[0239] A mixture of arylbromide (1 equiv.), B 2 pin 2 (1.2 equiv.), Pd(dppf)Cl 2 (0.05 equiv.), and KOAc (3 equiv.) in dioxane (10 mL / mmol arylbromide) was stirred at 110 °C for 2-5 h under N 2 until complete by LCMS. The reaction was filtered, concentrated in vacuo, and purified by silica gel chromotagraphy to provide the desired arylborane.Suzuki Coupling

[0240] "Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds" N. Miyaura; A. Suzuki Chem. Rev.1995, 957, 2457-2483.

[0241] Procedure A: To a solution of arylborane (1 equiv.) in dioxane (10 mL / mmol arylborane) was added arylbromide (1.2 equiv.), Pd(dppf)Cl 2 (0.1 equiv.), K 2 CO 3 (2 equiv.), and water (2 mL / mmol). The reaction was stirred at 110 °C for 3 h under N 2 . The reaction was worked up (washed with brine and extracted with EtOAc; combined extracts dried over Na 2 SO 4 , filtered, and concentrated) and purified by silica gel chromatography to provide the desired biaryl product.

[0242] Procedure B: To a solution of arylbromide (1 equiv.) and arylborane (1.1 equiv.) in dioxane (10 mL / mmol arylbromide) was added K 2 CO 3 (2 equiv.) in water (2 mL / mmol) and Pd(dppf)Cl 2 (0.1 equiv.). The reaction was stirred at 110 °C for 2 h under N 2 . The reaction was worked up (washed with brine and extracted with EtOAc; combined extracts dried over Na 2 SO 4 , filtered, and concentrated) and purified by silica gel chromatography to provide the desired biaryl product.

[0243] Procedure C: A mixture of arylbromide (1 equiv.), arylborane (2.0 equiv), K 2 CO 3 (3 equiv.), and Pd(dppf)Cl 2 (0.05 equiv.) in dioxane (10 mL / mmol arylbromide) and water (1 mL / mmol) was stirred at 110°C for 2 h under N 2 until complete by LCMS. The reaction was worked up (washed with brine and extracted with EtOAc; combined extracts dried over Na 2 SO 4 , filtered, and concentrated) and purified by silica gel chromatography to provide the desired biaryl product.Boc deprotection

[0244]

[0245] Boc-protected amine (1 equiv.) in DCM (4 mL / mmol amine) was added 4M HCl-dioxane (12 equiv.). The reaction was stirred for 1-2 h until complete by LCMS. The reaction was concentrated in vacuo to give the desired amine.t-butylsulfinyl deprotection

[0246]

[0247] To a solution of t-butylsulfinylamine (1 equiv.) in DCM (0.5 mL / mmol amine) was added 4M HCl-dioxane (1.7 equiv.). The reaction was stirred for 0.5-1 h until complete by LCMS. The reaction was concentrated and purified by prep HPLC to give the desired amine.Amide Bond Formation

[0248] "Peptide Coupling Reagents, More than a Letter Soup" A. El-Faham, F. Albericio Chem. Rev. 2011, 111, 11, 6557-6602; "Amide bond formation and peptide coupling" C. A. G. N. Montalbetti; V. Falque Tetrahedron 2005, 61, 10827-10852.

[0249] A mixture of amine (1 equiv.), carboxylic acid (1 equiv.), TCFH (2 equiv.), and NMI (4 equiv.) in CH 3 CN (10 mL / mmol amine) was stirred at room temperature for 1-2 h until complete by LCMS. The reaction was concentrated in vacuo and purified by silica gel chromatography to give the desired amide product.Ester Hydrolysis

[0250]

[0251] The ester (1 equiv.) was treated with LiOH-H 2 O (3-5 equiv.) in MeOH (1-3 mL / mmol ester) and water (1-3 mL / mmol ester) at room temperature for 1-5 h. The reaction was acidified with 1N HCl to pH=4-5 and concentrated. The residue was purified by prep HPLC to give the desired carboxylic acid product.Analytical Methods LCMS Analytical Methods

[0252] Final compounds were analyzed using LC / MS conditions, with UV detector monitoring at 214 nm and 254 nm, and mass spectrometry scanning 110-800 amu in ESI+ ionization mode.

[0253] LC / MS A: column: XBridge C18, 4.6 X 50 mm, 3.5 µm; mobile phase: A water (10 mM ammonium hydrogen carbonate), B CH 3 CN; gradient: 5%-95% B in 1.4 min, then 1.6 min hold; flow rate: 1.8 mL / min; oven temperature 50 °C.

[0254] LC / MS B: column: SunFire C18, 4.6 X 50 mm, 3.5 µm; mobile phase: A water (0.01% TFA), B CH 3 CN; gradient: 5%-95% B in 1.5 min, then 1.5 min hold; flow rate: 2.0 mL / min; oven temperature 50 °C.

[0255] LC / MS C: column: XBridge C18, 4.6 X 50 mm, 3.5 µm; mobile phase: A water (10 mM ammonium hydrogen carbonate), B CH3CN; gradient: 5%-95%B in 1.5min, then 1.5 min hold; flow rate: 1.8 mL / min; oven temperature 50 °C.

[0256] LC / MS D: column: Poroshell 120 EC-C138, 4.6 X 30 mm, 2.7 µm; mobile phase: A water (0.01% TFA), B CH 3 CN (0.01% TFA); gradient: 5%-95% B in 1.2 min, then 1.8 min hold; flow rate: 2.2 mL / min; oven temperature 50 °C.Example 2A. Preparation of Intermediates Preparation of ethyl (S)-3-(5-bromo-2-fluoro-3-methylphenyl)-3-((tert-butoxycarbonyl)amino)propanoate Step 1: 5-bromo-2-fluoro-3-methylbenzaldehyde

[0257]

[0258] To a mixture of 4-bromo-1-fluoro-2-methylbenzene (10.0 g, 52.9 mmol, 1.0 eq) in anhydrous THF (100.0 mL) under nitrogen atmosphere at -78 °C was added Lithium diisopropylamide (2.0 M, 39.7 mL, 79.4 mmol, 1.5 eq) dropwise over the period of 10 mins and stirred at -78°C for 1 hour. DMF (15.0 mL) was added dropwise and the mixture was stirred at -78°C for 2 hours. LCMS showed that the reaction was completed. The reaction mixture was quenched with a saturated NH 4 Cl solution (aq) (100 mL) at 0 °C, extracted with EtOAc (100 mL x 2). The organic layer was washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue obtained was purified by silica gel column (pet ether: EtOAc 9:1) to provide 5-bromo-2-fluoro-3-methylbenzaldehyde as a white solid (8.0 g). Yield 70% (ESI 218.9 [M+H] +< ).Step 2: (R, E)-N-(5-bromo-2-fluoro-3-methylbenzylidene)-2-methylpropane-2-sulfinamide

[0259]

[0260] To a mixture of 5-bromo-2-fluoro-3-methylbenzaldehyde (8.0 g, 36.9 mmol, 1.00 eq) and (R)-2-methylpropane-2-sulfinamide (5.4 g, 44.3 mmol, 1.2 eq) in anhydrous THF (80 mL) under nitrogen atmosphere was added Ti(OEt) 4 (12.6 g, 55.4 mmol, 1.50 eq) dropwise at room temperature with the temperature maintained below 30 °C. The reaction mixture was warmed to 40 °C and stirred for 1 hour. LCMS showed that the reaction was completed. Water (80 mL) and EtOAc (80 mL) was added into the mixture and stirred at room temperature for 5 mins. The mixture was filtered and washed with EtOAc (50 mL). The filtrate was separated. The organic layer was washed with water (100 mL) and brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo to give crude product (R, E)-N-(5-bromo-2-fluoro-3-methylbenzylidene)-2-methylpropane-2-sulfinamide as a yellow solid (12.0 g, crude) which was used in the next step without further purification. Yield 100% (ESI 320.0 [M+H] +< ).Step 3: ethyl (S)-3-(5-bromo-2-fluoro-3-methylphenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate

[0261]

[0262] To a mixture of Zn (12.2 g, 187.5 mmol, 5.0 eq) in anhydrous THF (200 mL) under nitrogen atmosphere was added chlorotrimethylsilane (0.8 g, 7.5 mmol, 0.2 eq) dropwise at room temperature. The mixture was stirred at 60 °C for 1 hour under nitrogen atmosphere and cooled to 20-30°C. Ethyl 2-bromoacetate (1.57 g, 9.4 mmol, 0.25 eq) was added dropwise at 20-30 °C. When the reaction mixture started to be exothermic, the rest of ethyl 2-bromoacetate (14.4 g, 86.3 mmol, 2.3 eq) was added dropwise during which time the reaction mixture was kept at 50-60 °C. After the completion of the addition, the reaction mixture was stirred at 60°C for 1 hour under nitrogen atmosphere. The reaction mixture was cooled to 0 °C, (R, E)-N-(5-bromo-2-fluoro-3-methylbenzylidene)-2-methylpropane-2-sulfinamide (12.0 g, 37.5 mmol) in anhydrous THF (30 mL) was added dropwise and stirred at 25 °C for 1 hour. LCMS showed that the reaction was completed. MTBE (150 mL) and a solution of citric acid (3 g) in water (100 mL) were added into the mixture. The mixture was separated. The aqueous layer was extracted with MTBE (150 mL x 2). The combined organic phase was washed with brine (200 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 3:1) to provide ethyl (S)-3-(5-bromo-2-fluoro-3-methylphenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (9.0 g). Yield 59% (ESI 408.0 [M+H] +< ).Step 4: ethyl (S)-3-amino-3-(5-bromo-2-fluoro-3-methylphenyl)propanoate

[0263]

[0264] To a solution of ethyl (S)-3-(5-bromo-2-fluoro-3-methylphenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (8.0 g, 19.6 mmol, 1.00 eq) in DCM (20 mL) was added HCl-dioxane (4 M, 20 mL, 80.0 mmol, 4.08 eq) and stirred at room temperature for 4 hours. LCMS showed that the reaction was completed. The mixture was filtered and concentrated in vacuo to give crude product ethyl (S)-3-amino-3-(5-bromo-2-fluoro-3-methylphenyl)propanoate as a yellow oil (8.0 g) used in the next step without further purification. Yield 100% (ESI 304.2 [M+H] +< ).Step 5: ethyl (S)-ethyl 3-(5-bromo-2-fluoro-3-methylphenyl)-3-(tert-butoxycarbonylamino)propanoate

[0265]

[0266] To a solution of ethyl (S)-3-amino-3-(5-bromo-2-fluoro-3-methylphenyl)propanoate (8.0 g, 19.6 mmol, 1.00 eq) in DCM (100 mL) was added DIEA (7.6 g, 59.0 mmol, 3.00 eq) and Boc 2 O (8.6 g, 39.2 mmol, 2.00 eq). The reaction mixture was stirred at room temperature for 16 hours. LCMS showed that the reaction was completed. The reaction mixture was diluted with DCM (200 mL) and washed with 0.5 N HCl (50 mL x 3), saturated NaHCO 3 (50 mL) and brine (50 mL). The organic phase was dried over Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 3:1) to provide ethyl (S)-3-(5-bromo-2-fluoro-3-methylphenyl)-3-((tert-butoxycarbonyl)amino)propanoate as a brown oil (6.0 g). Yield 75% (ESI 404.1 (M+H) +< ).Preparation of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate

[0267]

[0268] A mixture of ethyl (S)-3-(5-bromo-2-fluoro-3-methylphenyl)-3-((tert-butoxycarbonyl)amino)propanoate (1.0 g, 2.48 mmol, 1.0 eq), bis(pinacolato)diboron (756.28 mg, 2.98 mmol, 1.2 eq), Pd(dppf)Cl 2 (90.65 mg, 0.13 mmol, 0.05 eq) and KOAc (729.12 mg, 7.44 mmol, 3.0 eq) in 1,4-dioxane (20 mL) was stirred at 110 °C for 3 hours under nitrogen atmosphere. The reaction mixture was cooled to room temperature, filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 2:1) to give (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate as a colorless oil (1.0 g). Yield 89% (ESI 452.2 (M+H) +< ).Preparation of ethyl (S)-3-amino-3-(2',4-difluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2',4-difluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0269]

[0270] To a solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (300 mg, 0.66 mmol, 1.0 eq) in dioxane (5 mL) was added 2-bromo-1-fluoro-3-methylbenzene (150 mg, 0.79 mmol, 1.2 eq), Pd(dppf)Cl 2 (48 mg, 0.066 mmol, 0.1 eq), K 2 CO 3 (182 mg, 1.32 mmol, 2.0 eq) and water (1 mL). The reaction mixture was stirred at 110 °C for 3 hours under nitrogen atmosphere. Water (10 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 8:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2',4-difluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (210 mg). Yield 73% (ESI 334.1 [M+H-100] +< ).Step 2: ethyl (S)-3-amino-3-(2',4-difluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0271]

[0272] To a stirred solution of ethyl (,S)-3-((tert-butoxycarbonyl)amino)-3-(2',4-difluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (210 mg, 0.48 mmol, 1.0 eq) in DCM (2 mL) was added HCl-dioxane (4 M, 3.0 mL, 6.0 mmol, 12.5 eq). The mixture was stirred at room temperature for 2 hours. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(2',4-difluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (160 mg). Yield 99% (ESI 334.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(2'-cyano-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride Step 1: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-cyano-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0273]

[0274] To a solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (350 mg, 0.77 mmol, 1.0 eq) in dioxane (10 mL) was added 2-bromo-3-methylbenzonitrile (226 mg, 1.16 mmol, 1.5 eq), Pd(dppf)Cl 2 (56 mg, 0.077 mmol), K 2 CO 3 (193 mg, 1.4 mmol, 1.8 eq) and water (2 mL). The reaction mixture was stirred at 110 °C for 3 hours under nitrogen atmosphere. Water (20 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 4:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-cyano-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (260 mg). Yield 76% (ESI 341.1 [M+H-100] +< ).Step 2: ethyl (S)-3-amino-3-(2'-cyano-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride

[0275]

[0276] To a stirred solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-cyano-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (230 mg, 0.52 mmol, 1.0 eq) in DCM (2 mL) was added HCl-dioxane (4 M, 2.0 mL, 4.0 mmol, 7.7 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(2'-cyano-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride as a yellow oil (180 mg). Yield 91% (ESI 341.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(2'-chloro-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-chloro-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0277]

[0278] A mixture of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (1.0 g, 2.22 mmol, 1.00 eq), 2-bromo-1-chloro-3-methylbenzene (543 mg, 2.66 mmol, 1.20 eq), K 2 CO 3 (613 mg, 4.44 mmol, 2.0 eq) and Pd(dppf)Cl 2 (81 mg, 0.11 mmol, 0.05 eq) in dioxane (10 mL) and H 2 O (2 mL) was stirred at 110 °C for 2 hours under nitrogen atmosphere. Water (30 mL) was added and the solution was extracted with EtOAc (30 mL x 3). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 2:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-chloro-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (800 mg). Yield 80% (ESI 450.18 [M+H] +< ).Step 2: ethyl (S)-3-amino-3-(2'-chloro-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0279]

[0280] To a mixture of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-chloro-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (300 mg, 0.67 mmol, 1.00 eq) in DCM (9 mL) was added HCl-dioxane (4 M, 9.0 mL, 36.0 mmol, 53.73 eq) and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(2'-chloro-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a white solid (200 mg) used directly in the next reaction without further purification. Yield 86% (ESI 350.1[M+H] +< ).Preparation of ethyl (S)-3-amino-3-(2'-cyclopropyl-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-cyclopropyl-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0281]

[0282] A mixture of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-chloro-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (500 mg, 1.12 mmol, 1.00 eq), cyclopropylboronic acid (116 mg, 1.35 mmol, 1.20 eq), K 3 PO 4 (475 mg, 2.24 mmol, 2.00 eq), PCy 3 (31 mg, 0.11 mmol, 0.10 eq) and Pd(OAc) 2 (11 mg, 0.11 mmol, 0.10 eq) in dioxane (10 mL) and H 2 O (2 mL) was stirred at 110 °C for 36 hours under nitrogen atmosphere. Water (30 mL) was added and the solution was extracted with EtOAc (30 mL x 3). The combined organic phases were washed with brine (20 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 2:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-cyclopropyl-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (400 mg). Yield 79% (ESI 456.2 [M+H] +< ).Step 2: ethyl (S)-3-amino-3-(2'-cyclopropyl-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0283]

[0284] To a mixture of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-cyclopropyl-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (400 mg, 0.88 mmol, 1.0 eq) in DCM (9 mL) was added HCl-dioxane (4 M, 9.0 mL, 36.0 mmol, 40.9 eq) and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(2'-cyclopropyl-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a white solid (300 mg) used directly in the next reaction without further purification. Yield 96% (ESI 356.2 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4-fluoro-4'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride Step 1: ethyl (S)-3-amino-3-(2'-ethyl-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride

[0285]

[0286] To a solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (350 mg, 0.77 mmol, 1.0 eq) in dioxane (10 mL) was added 1-ethyl-2-iodo-3-methylbenzene (286 mg, 1.16 mmol, 1.5 eq), Pd(dppf)Cl 2 (56 mg, 0.077 mmol, 0.1 eq), K 2 CO 3 (193 mg, 1.4 mmol, 1.8 eq) and water (2 mL). The reaction mixture was stirred at 110 °C for 3 hours under nitrogen atmosphere. Water (10 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic phases were washed with brine (60 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 4:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-ethyl-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (240 mg). Yield 70% (ESI 344.2 [M+H-100] +< ).Step 2: ethyl (S)-3-amino-3-(2'-ethyl-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride

[0287]

[0288] To a stirred solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-ethyl-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (210 mg, 0.47 mmol, 1.0 eq) in DCM (2 mL) was added HCl-dioxane (4 M, 3.0 mL, 6.0 mmol, 12.8 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(2'-ethyl-4-fluoro-5,6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride as a colorless oil (170 mg). Yield 94% (ESI 344.1 [M+H] +< ).Preparation of (S)-ethyl 3-amino-3-(4-fluoro-2'-methoxy-5,6'-dimethylbiphenyl-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4-fluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoate

[0289]

[0290] A mixture of (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (1 g, 2.22 mmol, 1.0 eq), 2-bromo-1-methoxy-3-methylbenzene (666 mg, 3.33 mmol, 1.5 eq), K 2 CO 3 (919 mg, 6.66 mmol, 3.0 eq) and Pd(dppf)Cl 2 (162 mg, 0.222 mmol, 0.1 eq) in dioxane (15 mL) and H 2 O (1.5 mL) was stirred at 100°C under nitrogen atmosphere for 3 hours. LCMS showed the reaction was completed. The reaction mixture was cooled to room temperature. Water (50 mL) was added and the mixture was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 2:1) to provide (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(4-fluoro-2'-methoxy-5,6'-dimethylbiphenyl-3-yl)propanoate as a yellow oil (0.96 g). Yield 97% (ESI 346.1 [M+H] +< ).Step 2: (S)-ethyl 3-amino-3-(4-fluoro-2'-methoxy-5,6'-dimethylbiphenyl-3-yl)propanoate

[0291]

[0292] To a stirred solution of (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(4-fluoro-2'-methoxy-5,6'-dimethylbiphenyl-3-yl)propanoate (0.96 g, 2.15 mmol, 1.0 eq) in DCM (7 mL) was added HCl-dioxane (4 M, 2.15 mL, 4 eq) and stirred at 25 °C for 2 hours. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 40 g column (A: water 10 mM NH 4 HCO 3 , B: MeOH, 0~100%) to provide (S)-ethyl 3-amino-3-(4-fluoro-2'-methoxy-5,6'-dimethylbiphenyl-3-yl)propanoate as a yellow oil (0.6 g). Yield 81% (ESI 346.1 [M+H] +< ).Preparation of (S)-ethyl 3-amino-3-(4-fluoro-2'-methoxy-5-methyl-6'-(trifluoromethyl)biphenyl-3-yl)propanoate Step 1: 1-methoxy-2-nitro-3-(trifluoromethyl)benzene

[0293]

[0294] To a mixture of 2-nitro-3-(trifluoromethyl)phenol (1.5 g, 7.25 mmol, 1.0 eq) in acetone (20 mL) was added K 2 CO 3 (3 g, 21.75 mmol, 3 eq) and CH 3 I (5.15 g, 36.25 mmol, 5 eq) and stirred at room temperature for 16 hours. LCMS showed that the reaction was completed. The reaction mixture was filtered, washed with EtOAc (20 mL). The filtrate was concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 2:1) to provide 1-methoxy-2-nitro-3-(trifluoromethyl)benzene as a white solid (1.3 g). Yield 81% .Step 2: 2-methoxy-6-(trifluoromethyl)aniline

[0295]

[0296] To a mixture of 1-methoxy-2-nitro-3-(trifluoromethyl)benzene (1.3 g, 5.88 mmol, 1.0 eq) in EtOH (20 mL) was added 10%Pd / C (700 mg) and stirred at room temperature for 16 hours under H 2 atmosphere(2L, 1 atm). LCMS showed that the reaction was completed. The reaction mixture was filtered and the filtrated concentrated in vacuo to provide 2-methoxy-6-(trifluoromethyl)aniline as a white solid (0.75 g). Yield 67% (ESI 192.1 [M+H] +< ).Step 3: 2-bromo-1-methoxy-3-(trifluoromethyl)benzene

[0297]

[0298] To a mixture of 2-methoxy-6-(trifluoromethyl)aniline (700 mg, 3.66 mmol, 1.0 eq) in MeCN (15 mL) was added t-BuONO (565 mg, 5.49 mmol, 1.5 eq) and CuBr (628 mg, 4.39 mmol, 1.2 eq). The mixture was stirred at 60°C for 2 hours. LCMS showed that the reaction was completed. The reaction mixture was concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 10:1) to provide 2-bromo-1-methoxy-3-(trifluoromethyl)benzene as a colorless oil (400 mg). Yield 43%.Step 4: (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(4-fluoro-2'-methoxy-5-methyl-6'-(trifluoromethyl)biphenyl-3-yl)propanoate

[0299]

[0300] A mixture of 2-bromo-1-methoxy-3-(trifluoromethyl)benzene (400 mg, 1.57 mmol, 1.00 eq), (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (708 mg, 1.57 mmol, 1.0 eq), K 2 CO 3 (650 mg, 4.71 mmol, 3.0 eq) and Pd(dppf)Cl 2 (115 mg, 0.157 mmol, 0.1 eq) in dioxane (8 mL) and H 2 O (0.8 mL) was stirred at 110°C for 4 hours under nitrogen atmosphere. LCMS showed that the reaction was completed. The mixture was cooled to room temperature. Water (30 mL) was added and the mixture was extracted with EtOAc (30 mL x 3). The combined organic phases was washed with brine (30 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 10:1) to provide (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(4-fluoro-2'-methoxy-5-methyl-6'-(trifluoromethyl)biphenyl-3-yl)propanoate (400 mg) as a colorless oil. Yield 51% (ESI 400.1 [M-Boc] +< ).Step 5: (S)-ethyl 3-amino-3-(4-fluoro-2'-methoxy-5-methyl-6'-(trifluoromethyl)biphenyl-3-yl)propanoate

[0301]

[0302] To a stirred solution of (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(4-fluoro-2'-methoxy-5-methyl-6'-(trifluoromethyl)biphenyl-3-yl)propanoate (400 mg, 0.8 mmol, 1.00 eq) in DCM (6 mL) was added HCl-dioxane (4 M, 0.8 mL, 3.2 mmol, 4 eq) and stirred at room temperature for 2 hours. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 120g column (A: water 10 mM NH 4 HCO 3 , B: MeOH, 0~100%) to provide (S)-ethyl 3-amino-3-(4-fluoro-2'-methoxy-5-methyl-6'-(trifluoromethyl)biphenyl-3-yl)propanoate (280 mg) as a colorless oil. Yield 87% (ESI 400.1 [M+H] +< ).Preparation of (S)-ethyl 3-amino-3-(2',6'-dichloro-4-fluoro-5-methylbiphenyl-3-yl)propanoate Step 1: (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2',6'-dichloro-4-fluoro-5-methylbiphenyl-3-yl)propanoate

[0303]

[0304] To a mixture of methyl (S)-ethyl 3-(5-bromo-2-fluoro-3-methylphenyl)-3-(tert-butoxycarbonylamino)propanoate (0.5 g, 1.29 mmol, 1 eq) and 2,6-dichlorophenylboronic acid (0.26 g, 1.36 mmol, 1.1 eq) in dioxane (10 mL) was added a solution of K 2 CO 3 (0.34 g, 2.48 mmol, 2 eq) in H 2 O (2 mL) and Pd(dppf)Cl 2 (90 mg, 0.124 mmol, 0.1 eq). The mixture was heated to 110 °C for 2 hours under nitrogen atmosphere. The mixture was cooled to room temperature. Water (20 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic phases were concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 1:1) to provide (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2',6'-dichloro-4-fluoro-5-methylbiphenyl-3-yl)propanoate a colorless oil (0.550 g). Yield 94% (ESI 470.4 [M+H] +< ).Step 2: (S)-methyl 3-amino-3-(2',6'-dichloro-4-fluoro-5-methylbiphenyl-3-yl)propanoate

[0305]

[0306] To a mixture of methyl (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2',6'-dichloro-4-fluoro-5-methylbiphenyl-3-yl)propanoate (0.55 g, 1.21 mmol, 1 eq) in DCM (6 mL) was added HCl-dioxane (4 M, 3 mL, 12 mmol, 10 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to give crude product (S)-ethyl 3-amino-3-(2',6'-dichloro-4-fluoro-5-methylbiphenyl-3-yl)propanoate as a white solid (0.42 g) used directly in the next reaction without further purification. Yield 98% (ESI 370.3[M+H] +< ).Preparation of ethyl (S)-3-amino-3-(2',4-difluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: 2-fluoro-4,6-dimethylaniline

[0307]

[0308] A mixture of 2,4-dibromo-6-fluoroaniline (5.0 g, 18.59 mmol, 1.0 eq), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (3.5 M in THF, 21.2 mL, 74.36 mmol, 4.0 eq), Pd(dppf)Cl 2 (680 mg, 0.93 mmol, 0.05 eq) and K 2 CO 3 (7.71 g, 55.78 mmol, 3.0 eq) in dioxane (60 mL) and H 2 O (8 mL) was stirred at 110 °C for 12 hours under nitrogen atmosphere. The mixture was cooled to room temperature. Water (30 mL) was added and the solution was extracted with EtOAc (35 mL x 3). The combined organic phases were washed with brine (20 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 20:1) to provide 2-fluoro-4,6-dimethylaniline as a yellow oil (2.16 g). Yield 83.5% (ESI 140.2 [M+H] +< ).Step 2: 2-bromo-1-fluoro-3,5-dimethylbenzene

[0309]

[0310] To a stirred solution of 2-fluoro-4,6-dimethylaniline (1.0 g, 7.2 mmol, 1.0 eq) and CuBr 2 (4.8 g, 21.6 mmol, 3.0 eq) in MeCN (7 mL) was added tert-Butyl nitrite (1.68 g, 14.4 mmol, 2.0 eq) and stirred at 60 °C for 1 hour under nitrogen atmosphere. LCMS showed that the reaction was completed. The mixture was filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether) to provide 2-bromo-1-fluoro-3,5-dimethylbenzene as a yellow oil (560 mg). Yield 38%.Step 3: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2',4-difluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0311]

[0312] A mixture of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (556 mg, 1.23 mmol, 1.0 eq), 2-bromo-1-fluoro-3,5-dimethylbenzene (250 mg, 1.23 mmol, 1.0 eq), Pd(dppf)Cl 2 (45 mg, 0.062 mmol, 0.05 eq) and K 2 CO 3 (510 mg, 3.69 mmol, 3.0 eq) in dioxane (6 mL) and water (2 mL) was stirred at 110 °C for 2 hours under nitrogen atmosphere. Water (35 mL) was added and the solution was extracted with EtOAc (25 mL x 3). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 7:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2',4-difluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a yellow oil (365 mg). Yield 66% (ESI 348.1 [M+H-100] +< ).Step 4: ethyl (S)-3-amino-3-(2',4-difluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0313]

[0314] To a stirred solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2',4-difluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (720 mg, 1.29 mmol, 1.0 eq) in DCM (2 mL) was added HCl-dioxane (4 M, 2.0 mL, 4.0 mmol, 3.1 eq) and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(2',4-difluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a yellow oil (450 mg). Yield 93% (ESI 348.1 [M+H] +< ).Preparation of (S)-ethyl 3-amino-3-(2',6'-dichloro-4-fluoro-4',5-dimethylbiphenyl-3-yl)propanoate Step 1: 1,3-dichloro-2-iodo-5-methylbenzene

[0315]

[0316] To a mixture of 2,6-dichloro-4-methylaniline (2.5 g, 14.3 mmol, 1.0 eq) in acetonitrile (10 mL) and water (1 mL) was added 4-methylbenzenesulfonic acid (9.8 g, 57.1 mmol, 4 eq) and stirred at 0 °C for 10 mins. A solution of NaNO 2 (2.0 g, 28.6 mmol, 2 eq) in H 2 O (2 mL) was added dropwise and the mixture was stirred at 0 °C for 30 mins. Then a solution of potassium iodide (3.0 g, 17.9 mmol, 1.5 eq) in H 2 O (2 mL) was added and heated to 50 °C for 2 hours under nitrogen atmosphere. Water (20 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic phases were concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 1:1) to give 1,3-dichloro-2-iodo-5-methylbenzene as a colorless oil (1.8 g). Yield 44.2% (ESI 286.9[M+H]+).Step 2: (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2',6'-dichloro-4-fluoro-4',5-dimethylbiphenyl-3-yl)propanoate

[0317]

[0318] To a mixture of methyl (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (1.5 g, 3.43 mmol, 1 eq) and 1,3-dichloro-2-iodo-5-methylbenzene (2.0 g, 6.86 mmol, 2 eq) in dioxane (10 mL) was added a solution of K 2 CO 3 (1.9 g, 13.72 mmol, 4 eq) in H 2 O (2 mL) and Pd(dppf)Cl 2 (250 mg, 0.343 mmol, 0.1 eq). The mixture was heated to 110 °C for 2 hours under nitrogen atmosphere. Water (20 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic phases were concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 1:1) to give methyl (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2',6'-dichloro-4-fluoro-4',5-dimethylbiphenyl-3-yl)propanoate as a colorless oil (1.3 g). Yield 78.3% (ESI 484.4 [M+H] +< ).Step 3: (S)-ethyl 3-amino-3-(2',6'-dichloro-4-fluoro-4',5-dimethylbiphenyl-3-yl)propanoate

[0319]

[0320] To a mixture of methyl (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2',6'-dichloro-4-fluoro-4',5-dimethylbiphenyl-3-yl)propanoate (1.3 g, 2.76 mmol, 4 eq) in DCM (6 mL) was added HCl-dioxane (4 M, 3 mL, 12 mmol, 4.3 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to give crude (S)-ethyl 3-amino-3-(2',6'-dichloro-4-fluoro-4',5-dimethylbiphenyl-3-yl)propanoate as a white solid (1.0 g) used directly in the next reaction without further purification. Yield 91% (ESI 384.3 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0321]

[0322] A mixture of ethyl (S)-3-(5-bromo-2-fluoro-3-methylphenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (4.0 g, 9.8 mmol, 1.00 eq), (2,6-dimethylphenyl)boronic acid (2.9 g, 19.6 mmol, 2.00 eq), K 2 CO 3 (4.1 g, 29.4 mmol, 3.0 eq), Pd(dppf)Cl 2 (717 mg, 0.98 mmol, 0.05 eq) in dioxane (24 mL) and H 2 O (9 mL) was stirred at 110°C for 2 hours under nitrogen atmosphere. LCMS showed that the reaction was completed. The mixture was cooled to room temperature. Water (30 mL) was added and the solution was extracted with EtOAc (30 mL x 3). The combined organic phases were washed with brine (30 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 1:1) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (4.0 g) as a yellow oil. Yield 94% (ESI 434.1 [M+H] +< ).Step 2: ethyl (S)-3-amino-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0323]

[0324] To a stirred solution of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (4.0 g, 9.2 mmol, 1.00 eq) in DCM (6 mL) was added HCl-dioxane (4 M, 4 mL, 16.0 mmol, 1.7 eq). The mixture was stirred at room temperature for 30 mins. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 120g column (A: water 10 mM NH 4 HCO 3 , B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (2.0 g) as a colorless oil. Yield 61% (ESI 330.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0325]

[0326] A mixture of ethyl (S)-3-(5-bromo-2-fluoro-3-methylphenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (6.0 g, 14.7 mmol, 1.00 eq), (4-fluoro-2,6-dimethylphenyl)boronic acid (3.7g, 22.1 mmol, 1.5 eq), K 2 CO 3 (6.1 g, 44.1 mmol, 3.0 eq) and Pd(dppf)Cl 2 (1.1 g, 1.47 mmol, 0.01 eq) in dioxane (50 mL) and H 2 O (5 mL) was stirred at 110°C under nitrogen atmosphere for 1 hour. LCMS showed that the reaction was completed. The mixture was cooled to room temperature. Water (50 mL) was added and the solution was extracted with EtOAc (50 mL x 3). The combined organic phases were washed with brine (30 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 1:1) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a yellow oil (5.5 g). Yield 83% (ESI 452.0 (M+H) +< )Step 2: ethyl (S)-3-amino-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0327]

[0328] To the solution of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (5.5 g, 12.2 mmol, 1.00 eq) in DCM (6 mL) was added HCl-dioxane (4M, 6 mL, 24.0 mmol, 1.97 eq) and stirred at room temperature for 1 hour. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 120 g column (A: water / 0.01%TFA, B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(4,4'-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a yellow solid (4.0 g). Yield 95% (ESI 348.1 (M+H) +< ).Preparation of ethyl (S)-3-amino-3-(4'-chloro-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: 2-(4-chloro-2,6-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0329]

[0330] To a solution of 2-bromo-5-chloro-1,3-dimethylbenzene (4.0 g, 18.2 mmol, 1.0 eq) in anhydrous THF (40 mL) under nitrogen atmosphere was added n-BuLi (2 N, 11.0 mL, 22.0 mmol, 1.2 eq) at -78 °C. The reaction mixture was stirred at -78 °C for 40 mins and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (5.1 g, 27.5 mmol, 1.5 eq) in anhydrous THF (40 mL) was added and stirred at -78 °C for 3 hours. After completion, a saturated NH 4 Cl solution (aq) (100 mL) was added. The mixture was extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue obtained was purified by silica gel (petroleum ether: EtOAc 2:1) to give the desired 2-(4-chloro-2,6-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as a white solid (4.4 g). Yield 90%.Step 2: ethyl (S)-3-amino-3-(4'-chloro-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0331]

[0332] A mixture of ethyl (S)-3-amino-3-(5-bromo-2-fluoro-3-methylphenyl)propanoate (500 mg, 1.7 mmol, 1.0 eq), 2-(4-chloro-2,6-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (544 mg, 2.04 mmol, 1.2 eq), Pd(dppf)Cl 2 (62 mg, 0.085 mmol, 0.05 eq) and K 2 CO 3 (704 mg, 5.1 mmol, 3.0 eq) in 1,4-dioxane (10 mL) and water (2 mL) was stirred at 110 °C for 2 hours under nitrogen atmosphere. Water (20 mL) was added and the solution was extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 1:2) to provide ethyl (S)-3-amino-3-(4'-chloro-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (250 mg). Yield 41% (ESI 364.2 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4-fluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4-fluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoate

[0333]

[0334] A mixture of ethyl (S)-3-(5-bromo-2-fluoro-3-methylphenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (3.8 g, 9.3 mmol, 1.0 eq), mesitylboronic acid (3.05 g, 18.6 mmol, 2.0 eq), K 2 CO 3 (3.85 g, 27.9 mmol, 3.0 eq) and Pd(dppf)Cl 2 (340 mg, 0.465 mmol, 0.05 eq) in Dioxane (30 mL) and H 2 O (5 mL) was stirred at 110°C under nitrogen atmosphere for 2 hours. LCMS showed the reaction was complete. The reaction mixture was cooled to room temperature. Water (80 mL) was added and the mixture was extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (150 mL), dried over Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 1:1) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4-fluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoate as a yellow oil (3.1 g). Yield 75% (ESI 448.2 [M+H] +< ).Step 2: ethyl (S)-3-amino-3-(4-fluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoate

[0335]

[0336] To a stirred solution of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4-fluoro-2',4',5,6'-tetramethyl-[1,1'-biphenyl]-3-yl)propanoate (3.1 g, 6.94 mmol, 1.0 eq) in DCM (7 mL) was added HCl-dioxane (4 M, 6.8 mL, 3.9 eq) and stirred at 25 °C for 2 hours. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 40 g column (A: water 10 mM NH 4 HCO 3 , B: MeOH, 0~100%) to provide (S)-ethyl 3-amino-3-(4-fluoro-2',4',5,6'-tetramethylbiphenyl-3-yl)propanoate as a yellow oil (1.6 g). Yield 67% (ESI 344.2 [M+H] +< ).Example: Preparation of ethyl (S)-3-amino-3-(4-fluoro-2',5,6'-trimethyl-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate hydrochloride Step 1: 2,6-dimethyl-4-(trifluoromethyl)aniline

[0337]

[0338] A mixture of 2,6-dibromo-4-(trifluoromethyl)aniline (638 mg, 2.00 mmol, 1.0 eq), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (3.5 M in THF, 3.43 mL, 12.00 mmol, 6.0 eq), K 2 CO 3 (1.10 g, 7.96 mmol, 3.98 eq) and Pd(dppf)Cl 2 (245 mg, 0.30 mmol, 0.15 eq) in dioxane (6 mL) and water (1 mL) was stirred at 90 °C for 8 hours under nitrogen atmosphere. The mixture was filtered through a pad of Celite, washed with ethyl acetate (100 mL) and the filtrate was concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 20:1) to provide 2,6-dimethyl-4-(trifluoromethyl)aniline as a colorless oil (1.63 g). Yield 48% (ESI 190.1 (M+H) +< ).Step 2: 2-bromo-1,3-dimethyl-5-(trifluoromethyl)benzene

[0339]

[0340] A mixture of 2,6-dimethyl-4-(trifluoromethyl)aniline (793 mg, 4.19 mmol, 1.0 eq), tert-butyl nitrite (0.94 mL, 7.84 mmol, 1.9 eq) and copper(I) bromide (794 mg, 5.53 mmol, 1.3 eq) in anhydrous acetonitrile (16 mL) was stirred at 60 °C for 2 hours under nitrogen atmosphere. LCMS showed that the reaction was completed. The mixture was filtered through a pad of Celite and the filtrate was concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 6:1) to provide 2-bromo-1,3-dimethyl-5-(trifluoromethyl)benzene as a colorless oil (975 mg). Yield 46%. 1< H NMR (400 MHz, DMSO-d 6 ) δ: 7.55 (s, 2H), 2.42 (s, 6H).Step 3: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-2',5,6'-trimethyl-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0341]

[0342] To a solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (519 mg, 1.15 mmol, 1.0 eq) in dioxane (36 mL) was added 2-bromo-1,3-dimethyl-5-(trifluoromethyl)benzene (306 mg, 1.21 mmol, 1.1 eq), Pd(dppf)Cl 2 (188 mg, 0.23 mmol, 0.2 eq), K 2 CO 3 (477 mg, 3.45 mmol, 3.0 eq) and water (3.6 mL). The reaction mixture was stirred at 110 °C for 18 hours under nitrogen atmosphere. The mixture was filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 6:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-2',5,6'-trimethyl-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate as a light brown oil (308 mg). Yield 54%. (ESI 398.1 [M+H-100] +< ).Step 5: ethyl (S)-3-amino-3-(4-fluoro-2',5,6'-trimethyl-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate hydrochloride

[0343]

[0344] To a stirred solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-2',5,6'-trimethyl-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate (308 mg, 0.62 mmol, 1.0 eq) in DCM (4 mL) was added HCl-dioxane (4 M, 4.0 mL, 16.0 mmol, 25.8 eq). The mixture was stirred at room temperature for 2 hours. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(4-fluoro-2',5,6'-trimethyl-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate hydrochloride as a yellow oil (260 mg). Yield 97% (ESI 398.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4'-cyclopropyl-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: 4-cyclopropyl-2,6-dimethylaniline

[0345]

[0346] To a mixture of 4-bromo-2,6-dimethylaniline (2.0 g, 10.0 mmol, 1.0 eq), cyclopropylboronic acid (1.03 g, 12.0 mmol, 1.2 eq) in toluene (15 mL) under nitrogen atmosphere was added a solution of K 3 PO 4 (4.2 g, 20.0 mmol, 2.0 eq) in H 2 O (3 mL), PCy 3 (280.0 mg, 1.0 mmol, 0.1 eq) and Pd(OAc) 2 (224.0 mg, 1.0 mmol, 0.1 eq). The mixture was stirred at 100 °C for 4 hours under nitrogen atmosphere. Water (30 mL) was added and the solution was extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 2:1) to provide 4-cyclopropyl-2,6-dimethylaniline (0.8 g) used in the next step without further purification. Yield 93% (ESI 162.2 [M+H] +< ).Step 2: 2-bromo-5-cyclopropyl-1,3-dimethylbenzene

[0347]

[0348] To a mixture of 4-cyclopropyl-2,6-dimethylaniline (800.0 mg, 4.9 mmol, 1.0 eq) in ACN (10 mL) and H 2 O (1 mL) was added p-toluenesulphonic acid (3.4 g, 19.8 mmo, 4.0 eq). The mixture was stirred at 0 °C for 10 mins under under nitrogen atmosphere. A solution of NaNO 2 (685.0 mg, 9.93 mmol, 2.0 eq) in H 2 O (2 mL) was added dropwise and the mixture was stirred 0 °C for 30 mins. CuBr (4.4 g, 19.8 mmol, 4.0 eq) was added to the reaction mixture and stirred at room temperature for 4 hours. Water (50 mL) was added and the solution was extracted with DCM (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 19:1) to provide 2-bromo-5-cyclopropyl-1,3-dimethylbenzene as a yellow oil (800.0 mg) used in the next step without further purification. Yield 49% (ESI 225.1 (M+H) +< , 227.1 (M+H) +< ).Step 3: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4'-cyclopropyl-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0349]

[0350] To a mixture of 2-bromo-5-cyclopropyl-1,3-dimethylbenzene (800 mg, 3.6 mmol, 1.0 eq) and ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (1.6 g, 3.6 mmol, 1.0 eq) in 1,4-dioxane (10 mL) under nitrogen atmosphere was added a solution of K 2 CO 3 (1.0 g, 7.2 mmol, 2.0 eq) in H 2 O (1 mL) and Pd(dppf)Cl 2 (260 mg, 0.36 mmol, 0.1 eq). The mixture was stirred at 110 °C for 2 hours under nitrogen atmosphere. Water (30 mL) was added and the solution was extracted with EtOAc (50 mL x 3). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 19:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4'-cyclopropyl-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoateas a brown oil (500 mg). Yield 30% (ESI 370.1 [M-100+H] +< ).Step 4: ethyl (S)-3-amino-3-(4'-cyclopropyl-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride

[0351]

[0352] To a stirred solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4'-cyclopropyl-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (900 mg, 1.91 mmol, 1.0 eq) in DCM (5 mL) was added HCl-dioxane (4 M, 5.0 mL, 20.0 mmol, 10.47 eq) and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(4'-cyclopropyl-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride as a green-yellow foam (710 mg). Yield 91% (ESI 370.2 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4-fluoro-4'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride Step 1: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-4'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0353]

[0354] To a solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (350 mg, 0.77 mmol, 1.0 eq) in dioxane (10 mL) was added 2-bromo-5-methoxy-1,3-dimethylbenzene (166 mg, 0.77 mmol, 1.0 eq), Pd(dppf)Cl 2 (56 mg, 0.077 mmol, 0.1 eq), K 2 CO 3 (213 mg, 1.54 mmol, 2.0 eq) and water (2 mL). The reaction mixture was stirred at 110°C for 3 hours under nitrogen atmosphere. Water (10 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (60 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 7:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-4'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (230 mg). Yield 65% (ESI 360.2 [M+H-100] +< ).Step 2: ethyl (S)-3-amino-3-(4-fluoro-4'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride

[0355]

[0356] To a stirred solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-4'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (200 mg, 0.43 mmol, 1.0 eq) in DCM (7 mL) was added HCl-dioxane (4 M, 2.0 mL, 4.0 mmol, 9.3 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(4-fluoro-4'-methoxy-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride as a yellow oil (160 mg). Yield 93% (ESI 360.2 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4'-cyano-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4'-cyano-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0357]

[0358] A mixture of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (450 mg, 1 mmol, 1.0 eq), 4-bromo-3,5-dimethylbenzonitrile (316 mg, 1.5 mmol, 1.5 eq), Pd(dppf)Cl 2 (37 mg, 0.05 mmol, 0.05 eq) and K 2 CO 3 (414 mg, 3 mmol, 3.0 eq) in 1,4-dioxane (8 mL) and water (2 mL) was stirred at 110°C for 2 hours under nitrogen atmosphere. Water (10 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 1:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4'-cyano-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (320 mg). Yield 70% (ESI 455.2 [M+H] +< ).Step 2: ethyl (S)-3-amino-3-(4'-cyano-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0359]

[0360] To a stirred solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4'-cyano-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (320 mg, 0.7 mmol, 1.0 eq) in DCM (2 mL) was added HCl-dioxane (4 M, 2.0 mL, 4.0 mmol, 5.7 eq). The mixture was stirred at room temperature for 2 hours. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(4'-cyano-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (250 mg). Yield 100% (ESI 355.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4'-((dimethylamino)methyl)-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-4'-formyl-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0361]

[0362] A mixture of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (465 mg, 1.03 mmol, 1.1 eq), 4-bromo-3,5-dimethylbenzaldehyde (200 mg, 0.93 mmol, 1.0 eq), K 2 CO 3 (259 mg, 1.87 mmol, 2.0 eq) and 1,1'-Bis(diphenylphosphino) ferrocene-palladium(II)dichloride dichloromethane complex (68 mg, 0.09 mmol, 0.1 eq) in dioxane (10 mL) and H 2 O (1 mL) was stirred at 80 °C for 3 hours under nitrogen atmosphere. LCMS showed that the reaction was completed. The mixture was cooled to room temperature. Water (50 mL) was added and the solution was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 1:3) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-4'-formyl-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a yellow oil (300 mg). Yield 64% (ESI 358.1 [M+H-100] +< )Step 2: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4'-((dimethylamino)methyl)-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0363]

[0364] A mixture of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-4'-formyl-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (1.3 g, 2.8 mmol, 1.0 eq) and dimethylamine hydrochloride (233 mg, 2.9 mmol, 1.05 eq) in DCE (10 mL) was stirred at room temperature for 30 mins. Sodium triacetoxyborohydride (1.2 g, 5.6 mmol, 2.0 eq) was added and stirred at room temperature for 16 hours. The solvent was removed in vacuo and the residue was purified by silica gel column (DCM: MeOH 9:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4'-((dimethylamino)methyl)-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a yellow oil (800 mg). Yield 58.7% (ESI 487.2 (M+H) +< ).Step 3: ethyl (S)-3-amino-3-(4'-((dimethylamino)methyl)-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0365]

[0366] To a stirred solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4'-((dimethylamino)methyl)-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (800 mg, 1.64 mmol, 1.0 eq) in DCM (10 mL) was added HCl-dioxane (4 M, 3mL, 12.0 mmol) and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase on a C18 / 40 g column (A: water 10 mM NH 4 HCO 3 , B: MeOH, 0~100%) to provideethyl (S)-3-amino-3-(4'-((dimethylamino)methyl)-4-fluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a white solid (600 mg). Yield 94% (ESI 387.2 (M+H) +< ).Preparation of ethyl (S)-3-amino-3-(4-fluoro-4'-((3-fluoroazetidin-1-yl)methyl)-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-4'-((3-fluoroazetidin-1-yl)methyl)-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0367]

[0368] A mixture of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-4'-formyl-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (1.3 g, 2.8 mmol, 1.0 eq) and 3-fluoroazetidine hydrochloride (233 mg, 2.9 mmol, 1.05 eq) in DCM (10 mL) was stirred at room temperature for 30 mins. Sodium triacetoxyborohydride (1.2 g, 5.6 mmol, 2.0 eq) was added and stirred at room temperature for 16 hours. The solvent was removed in vacuo and the residue was purified by silica gel column (DCM: MeOH 9:1) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4-fluoro-4'-((3-fluorocyclobutyl)methyl)-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as yellow oil (800 mg). Yield 54.7% (ESI 517.2 [M+H] +< ).Step 2: ethyl (S)-3-amino-3-(4-fluoro-4'-((3-fluoroazetidin-1-yl)methyl)-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0369]

[0370] To a solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(4-fluoro-4'-((3-fluoroazetidin-1-yl)methyl)-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (800 mg, 1.5 mmol, 1.0 eq) in DCM (10 mL) was added HCl-dioxane (4M, 10.0 mL, 40.0 mmol, 26.7 eq) and stirred at room temperature for 1 hour. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 120 g column (A: water / 0.01%TFA, B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(4-fluoro-4'-((3-fluoroazetidin-1-yl)methyl)-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a white solid (500 mg). Yield 78% (ESI 417.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(2'-cyclopropyl-4-fluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: 2-bromo-1-chloro-3,5-dimethylbenzene

[0371]

[0372] To a mixture of 2-chloro-4,6-dimethylaniline (3.0 g, 19.3 mmol, 1.00 eq) and CuBr 2 (21.5 g, 96.5 mmol, 5.00 eq) in ACN (50 mL) was added t-BuONO (5.96 g, 58.9 mmol, 3.00 eq) and stirred at 60 °C for 2 hours under nitrogen atmosphere. The mixture was filtered through a pad of Celite and the filtrate was concentrated in vacuo. The residue was purified by silica gel column (pet ether 100%) to give compound 2-bromo-1-chloro-3,5-dimethylbenzene as colorless oil (2.8 g). Yield: 67% (ESI 220 [M+H]+).Step 2: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-chloro-4-fluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0373]

[0374] To a mixture of 2-bromo-1-chloro-3,5-dimethylbenzene (483 mg, 2.2 mmol, 1.10 eq), ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (902 mg, 2.0 mmol, 1.00 eq) in dioxane (10 mL) under nitrogen atmosphere was added a solution of K 2 CO 3 (552 mg, 4.0 mmol, 2.00 eq) in H 2 O (5 mL) and Pd(dppf)Cl 2 (146 mg, 0.2 mmol, 0.10 eq). The mixture was stirred at 100 °C for 2 hours under nitrogen atmosphere. Water (30 mL) was added and the solution was extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (70 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 10:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-chloro-4-fluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as colorless oil (880 mg). Yield 95% (ESI 364 [M-100+H] +< ).Step 3: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-cyclopropyl-4-fluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0375]

[0376] To a solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-chloro-4-fluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (880 mg, 1.9 mmol, 1.00 eq), cyclopropylboronic acid (327 mg, 3.8 mmol, 2.00 eq) in toluene (10 mL) under nitrogen atmosphere was added a solution of K 3 PO 4 (807 mg, 3.8 mmol, 2.00 eq) in H 2 O (2 mL), Pd(OAc) 2 (43 mg, 0.19 mmol, 0.10 eq) and PCy 3 (107 mg, 0.38 mmol, 0.20 eq). The mixture was stirred at 110 °C for 36 hours under nitrogen atmosphere. Water (30 mL) was added and the solution was extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (70 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether EtOAc 2:1) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-cyclopropyl-4-fluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a gray solid (625 mg). Yield 70% (ESI 370 [M-100+H] +< ).Step 4: ethyl (S)-3-amino-3-(2'-cyclopropyl-4-fluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride

[0377]

[0378] To a solution of ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2'-cyclopropyl-4-fluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (250 mg, 0.53 mmol, 1.00 eq) in 1,4-dioxane (6 mL) was added HCl-dioxane (4M4.0 mL, 16.0 mmol, 30.2 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(2'-cyclopropyl-4-fluoro-4',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride as a white solid (215 mg), used directly in the next reaction without further purification. Yield 100% (ESI 370 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: 2-bromo-6-fluoro-3-methylbenzaldehyde

[0379]

[0380] To a mixture of 2-bromo-4-fluoro-1-methylbenzene (5.0 g, 26.5 mmol, 1.00 eq) in anhydrous THF (50 mL) under nitrogen atmosphere was added lithium diisopropylamide (2.0 M, 14.6 mL, 29.2 mmol, 1.10 eq) at -78°C and stirred at -78°C for 1 hour. DMF (3.87 g, 53 mmol, 2.00 eq) was added to the reaction mixture at -78°C and stirred at -78°C for 0.5 hour, then slowly warmed to room temperature and stirred for 2 hours. The reaction was quenched with water (20 mL), extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo to give the crude product 2-bromo-6-fluoro-3-methylbenzaldehyde as a brown liquid (4.2 g). Yield 73%. 1< H NMR (400 MHz, MeOD) δ 10.02 (s, 1H), 7.45-7.17 (m, 1H), 7.05-7.00 (m, 1H), 2.26 (s, 3H).Step 2: (2-bromo-6-fluoro-3-methylphenyl)methanol

[0381]

[0382] To a mixture of 2-bromo-6-fluoro-3-methylbenzaldehyde (3.0 g, 13.8 mmol, 1.00 eq) in MeOH (30 mL) under nitrogen atmosphere was added NaBH 4 (1.5 g, 41.4 mmol, 3.00 eq) at 0°C and stirred at room temperature for 2 hours. The mixture was quenched with water (50 mL), extracted with EtOAc (50 mL x 3). The combined organic phase was washed with brine (80 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 10:1) to provide (2-bromo-6-fluoro-3-methylphenyl)methanol as a white solid (2.7 g). Yield 90%Step 3: (2-bromo-3-(bromomethyl)-4-fluoro-1-methylbenzene

[0383]

[0384] To a mixture of (2-bromo-6-fluoro-3-methylphenyl)methanol (3.2 g, 14.6 mmol, 1.00 eq) in THF (50 mL) under nitrogen atmosphere was added PBr 3 (3 mL, 29.2 mmol, 2.00 eq) at room temperature and stirred for 1 hour. The reaction mixture was concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 99:1) to provide 2-bromo-3-(bromomethyl)-4-fluoro-1-methylbenzene as a white solid (3.58 g). Yield 90% 1< H NMR (400 MHz, MeOD) δ 7.33-7.30 (m, 1H), 7.09-7.04 (m, 1H), 4.72 (d, J=2.0 Hz, 2H), 2.40 (s, 3H).Step 4: 2-bromo-4-fluoro-1,3-dimethylbenzene

[0385]

[0386] To a mixture of 2-bromo-3-(bromomethyl)-4-fluoro-1-methylbenzene (2.0 g, 7.09 mmol, 1.00 eq) in DMF (20 mL) was added NaBH 4 (0.536 g, 14.18 mmol, 2.00 eq) and AgNO 3 (2.4 g, 14.18 mmol, 2.00 eq) at room temperature. The reaction was stirred at room temperature for 0.5 hour. The mixture was quenched with water (50 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (DCM 100%) to provide 2-bromo-4-fluoro-1,3-dimethylbenzene as colorless oil (1.00 g). Yield 69% 1< H NMR (400 MHz, CDCl 3 ) δ 7.09 - 7.01 (m, 1H), 6.90 (t, J = 8.7 Hz, 1H), 2.37 (s, 3H), 2.34 (d, J = 2.4 Hz, 3H).Step 5: ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0387]

[0388] To a mixture of 2-bromo-4-fluoro-1,3-dimethylbenzene (800 mg, 3.93 mmol, 1.00 eq), ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (1.77 g, 3.93 mmol, 1.00 eq) in dioxane (12 mL) under nitrogen atmosphere was added a solution of K 2 CO 3 (1.08 g, 7.86 mmol, 2.00 eq) in H 2 O (2 mL) and Pd(dppf)Cl 2 (658 mg, 0.39 mmol, 0.10 eq). The mixture was stirred at 100 °C for 2 hours under nitrogen atmosphere. Water (30 mL) was added and the solution was extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (70 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by reverse phase HPLC on a C18 / 40 g column (A: water 10 mM NH 4 HCO 3 , B: MeOH, 0~100%) to provide ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as colorless oil (1.2 g). Yield 68% (ESI 348.1 [M-100+H] +< ).Step 6: ethyl (S)-3-amino-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride

[0389]

[0390] To a mixture of product ethyl (S)-3-((tert-butoxycarbonyl)amino)-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (1.2 g, 2.68 mmol, 1.00 eq) in 1,4-dioxane (6 mL) was added HCl-dioxane (4M 4.0 mL, 16.0 mmol, 5.97 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(3',4-difluoro-2',5,6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride (1.0 g crude) used directly in the next reaction without further purification. (ESI 348.2 [M+H] +< ).Preparation of (S)-ethyl 3-amino-3-(4-fluoro-3'-methoxy-2',5,6'-trimethylbiphenyl-3-yl)propanoate Step 1: 1-bromo-2,4-dimethyl-3-nitrobenzene

[0391]

[0392] To a mixture of 1,3-dimethyl-2-nitrobenzene (10 g, 66 mmol, 1.0 eq) in DCM (100 mL) was added FeBr 3 (390 mg, 211.32 mmol, 0.02 eq) and Fe (1.12 g, 20 mmol, 0.3 eq). Br 2 (11.6 g, 72.6 mmol, 1.1 eq) was added dropwise and stirred at 60°C for 16 hours. The reaction mixture was concentrated in vacuo and the residue was purified by silica gel column (pet ether) to provide 1-bromo-2,4-dimethyl-3-nitrobenzene as a white solid (10 g). Yield 66%.Step 2: 1-methoxy-2,4-dimethyl-3-nitrobenzene

[0393]

[0394] To a mixture of 1-bromo-2,4-dimethyl-3-nitrobenzene (8 g, 35 mmol, 1.0 eq) in MeOH (80 mL) and DMF (80 mL) was added NaOCH 3 (5.67 g, 105 mmol, 3 eq) and CuBr (1 g, 7 mmol, 0.2 eq) at room temperature. The mixture was stirred at 110°C for 16 hours. The reaction mixture was filtered. The filtrate was diluted with water (100 mL), extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (100% pet ether) to provide 1-methoxy-2,4-dimethyl-3-nitrobenzene as a colorless oil (5.8 g). Yield 91% (ESI 182.2 [M+H] +< ).Step 3: 3-methoxy-2,6-dimethylaniline

[0395]

[0396] To a mixture of 1-methoxy-2,4-dimethyl-3-nitrobenzene (5.8 g, 32 mmol, 1.0 eq) in MeOH (60 mL) and H 2 O (6 mL) at 0°C was added NH 4 Cl (5.18 g, 96 mmol, 3.0 eq) and Zn (20.8 g, 320 mmol, 10 eq). The mixture was stirred at room temperature for 4 hours. LCMS showed that the reaction was completed. The reaction mixture was filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 1:1) to provide 3-methoxy-2,6-dimethylaniline as yellow oil (2.8 g). Yield 58% (ESI 152.2[M+H] +< ).Step 4: 2-bromo-4-methoxy-1,3-dimethylbenzene

[0397]

[0398] To a mixture of 3-methoxy-2,6-dimethylaniline (2 g, 13.24 mmol, 1.0 eq) in MeCN (30 mL) was added t-BuONO (2.06 g, 20 mmol, 1.5 eq) at 0°C, then CuBr(2.27 g, 15.89 mmol, 1.2 eq) was added. The mixture was stirred at 60°C for 2 hours. LCMS showed that the reaction was completed. The reaction mixture was concentrated in vacuo and purified by silica gel column (pet ether) to provide 2-bromo-4-methoxy-1,3-dimethylbenzene as a colorless oil (800 mg). Yield 28% .Step 5: (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(4-fluoro-3'-methoxy-2',5,6'-trimethylbiphenyl-3-yl)propanoate

[0399]

[0400] A mixture of 2-bromo-4-methoxy-1,3-dimethylbenzene (700 mg, 3.27 mmol, 1.00 eq), (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (1.47 g, 3.27 mmol, 1.0 eq), K 2 CO 3 (1.35 g, 9.81 mmol, 3 eq) and Pd(dppf)Cl 2 (239 mg, 0.327 mmol, 0.1 eq) in dioxane (10 mL) and H 2 O (1 mL) was stirred at 110°C for 4 hours under nitrogen atmosphere. LCMS showed that the reaction was completed. The mixture was cooled to room temperature. Water (30 mL) was added and the solution was extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 5:1) to provide (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(4-fluoro-3'-methoxy-2',5,6'-trimethylbiphenyl-3-yl)propanoate (1 g) as a colorless oil. Yield 67% (ESI 360.1 [M-Boc+1] +< ).Step 6: (S)-ethyl 3-amino-3-(4-fluoro-3'-methoxy-2',5,6'-trimethylbiphenyl-3-yl)propanoate

[0401]

[0402] To a stirred solution of (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(4-fluoro-3'-methoxy-2',5,6'-trimethylbiphenyl-3-yl)propanoate (1 g, 2.18 mmol, 1.00 eq) in DCM (8 mL) was added HCl-dioxane (4 M, 2.18 mL, 8.72 mmol, 4 eq). The mixture was stirred at room temperature for 2 hours. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 80g column (A: water 10 mM NH 4 HCO 3 , B: MeOH, 0~100%) to provide (S)-ethyl 3-amino-3-(4-fluoro-3'-methoxy-2',5,6'-trimethylbiphenyl-3-yl)propanoate (600 mg) as a colorless oil. Yield 77% (ESI 360.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(6'-cyano-4-fluoro-2',3',5-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(6'-cyano-4-fluoro-2',3',5-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0403]

[0404] A mixture of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (1.7 g, 3.6 mmol,, 2.0 eq), 2-chloro-3,4-dimethylbenzonitrile (300 mg, 1.8 mmol, 1.0 eq), K 3 PO 4 (1.2 g, 5.4 mmol, 3.0 eq) and XPhosPdG2 (140 mg, 0.18 mmol, 0.1 eq) in dioxane (30 mL) and H 2 O (3 mL) was stirred at 80 °C for 2 hours under nitrogen atmosphere. LCMS showed that the reaction was completed. The mixture was cooled to room temperature. Water (20 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 1:1) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(6'-cyano-4-fluoro-2',3',5-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (500 mg) as a yellow oil. Yield 60% (ESI 459.3 [M+H] +< ).Step 2: ethyl (S)-3-amino-3-(6'-cyano-4-fluoro-2',3',5-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0405]

[0406] To a stirred solution of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(6'-cyano-4-fluoro-2',3',5-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (500 mg, 1.1 mmol, 1.0 eq) in DCM (10 mL) was added HCl-dioxane (4 M, 10 mL, 40.0 mmol, 36.4 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 40 g column (A: water 10 mM NH 4 HCO 3 , B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(6'-cyano-4-fluoro-2',3',5-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (200 mg) as a colorless oil. Yield 51.8% (ESI 355.2 [M+H] +< ).Preparation of (S)-ethyl 3-amino-3-(3',4-difluoro-2',4',5,6'-tetramethylbiphenyl-3-yl)propanoate Step 1: (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(3',4-difluoro-2',4',5,6'-tetramethylbiphenyl-3-yl)propanoate

[0407]

[0408] To a mixture of (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (500 mg, 1.14 mmol, 1 eq) and 2-bromo-4-fluoro-1,3,5-trimethylbenzene (309 mg, 1.43 mmol, 1.2 eq) in dioxane (10 mL) was added a solution of K 2 CO 3 (314.6 mg, 2.28 mmol, 2 eq) in H 2 O (2 mL) and Pd(dppf)Cl 2 (80 mg, 0.11 mmol, 0.1 eq). The mixture was heated to 110 °C for 2 hours under nitrogen atmosphere. Water (20 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic layers were concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 1:1) to give methyl (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(3',4-difluoro-2',4',5,6'-tetramethylbiphenyl-3-yl)propanoate as a colorless oil (500 mg). Yield 97.8% (ESI 461.5 [M+H] +< ).Step 2: (S)-ethyl 3-amino-3-(3',4-difluoro-2',4',5,6'-tetramethylbiphenyl-3-yl)propanoate

[0409]

[0410] To a mixture of methyl (S)-methyl 3-(tert-butoxycarbonylamino)-3-(3',4-difluoro-2',4',5,6'-tetramethylbiphenyl-3-yl)propanoate (500 mg, 1.12 mmol, 1 eq) in DCM (6 mL) was added HCl-dioxane (4 M, 3 mL, 12 mmol, 10 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo to give crude product (S)-ethyl 3-amino-3-(3',4-difluoro-2',4',5,6'-tetramethylbiphenyl-3-yl)propanoate as a white solid (300 mg) used directly in the next reaction without further purification. Yield 77% (ESI 361.4s [M+H] +< ).Preparation of ethyl (S)-3-(5-bromo-3-chloro-2-fluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate Step 1: (R, E)-N-(5-bromo-3-chloro-2-fluorobenzylidene)-2-methylpropane-2-sulfinamide

[0411]

[0412] To a mixture of 5-bromo-3-chloro-2-fluorobenzaldehyde (10.0 g, 42.2 mmol, 1.00 eq) and (R)-2-methylpropane-2-sulfinamide (5.6 g, 46.4 mmol, 1.1 eq) in anhydrous THF (100 mL) under nitrogen atmosphere was added Ti(OEt) 4 (14.4 g, 63.3 mmol, 1.50 eq) dropwise at room temperature and the temperature maintained below 30 °C. The reaction mixture was warmed to 35 °C and stirred for 1 hour. LCMS showed that the reaction was completed. Water (100 mL) and EtOAc (100 mL) were added into the mixture and stirred at room temperature for 5 mins. The mixture was filtered and washed with EtOAc (50 mL). The filtrate was separated. The organic layer was washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 4:1) to provide (R, E)-N-(5-bromo-3-chloro-2-fluorobenzylidene)-2-methylpropane-2-sulfinamide as a yellow oil (14.0 g). Yield 98% (ESI 341.9 (M+H) +< ).Step 2: ethyl (S)-3-(5-bromo-3-chloro-2-fluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate

[0413]

[0414] To a mixture of Zn (13.0 g, 205.5 mmol, 5.00 eq) in anhydrous THF (200 mL) under nitrogen atmosphere was added chlorotrimethylsilane (888 mg, 8.22 mmol, 0.2 eq) dropwise at room temperature and stirred at 50 °C under nitrogen atmosphere for 1 hour. The mixture was cooled to 20-30°C. Ethyl 2-bromoacetate (17.1 g, 102.7 mmol, 2.50 eq) was added dropwise at room temperature under nitrogen atmosphere and stirred at 60 °C under for 1 hour. The reaction mixture was cooled to room temperature. A solution of (R, E)-N-(5-bromo-3-chloro-2-fluorobenzylidene)-2-methylpropane-2-sulfinamide (14.0 g, 41.1 mmol, 1.00 eq) in anhydrous THF (20 mL) was added dropwise into the mixture at room temperature under nitrogen atmosphere and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. Water (100 mL) and EtOAc (100 mL) was added into the mixture and stirred at room temperature for 5 mins. The mixture was filtered. The filtrate was extracted with EtOAc (100 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 4:1) to provide ethyl (S)-3-(5-bromo-3-chloro-2-fluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate as a yellow oil (12.0 g). Yield 73% (ESI 429.9 (M+H) +< ).Preparation of ethyl (S)-3-amino-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0415]

[0416] A mixture of ethyl (S)-3-(5-bromo-3-chloro-2-fluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (4.0 g, 9.6 mmol, 1.00 eq), K 2 CO 3 (8.0 g, 57.6 mmol, 2.0 eq) Pd(dppf)Cl 2 (1.4 g, 1.9 mmol, 0.1 eq) and (2,6-dimethylphenyl)boronic acid (2.8 g, 19.2 mmol, 2.00 eq) in dioxane (40 mL) and H 2 O (4 mL) was stirred at 80 °C for 16 hours under nitrogen atmosphere. The reaction mixture was cooled to room temperature and poured into 50 mL of water and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 10:1) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a yellow oil (3.0 g). Yield 71% (ESI 454.1 (M+H) +< )Step 2: ethyl (S)-3-amino-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0417]

[0418] To a mixture of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (3.0 g, 43.66 mmol, 1.0 eq) in DCM (20 mL) was added HCl-dioxane (4 M, 20 mL, 80 mmol, 1.8 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 120g column (A: water 10 mM NH 4 HCO 3 , B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(5-chloro-4-fluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a white solid (1.8 g). Yield 78% (ESI 350.0 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(5-chloro-4,4'-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-chloro-4,4'-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0419]

[0420] To a mixture of ethyl (S)-3-(5-bromo-3-chloro-2-fluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (2.0 g, 4.66 mmol, 1.0 eq) and (4-fluoro-2,6-dimethylphenyl)boronic acid (940 mg, 5.59 mmol, 1.2 eq) in dioxane (20 mL) was added a solution of K 2 CO 3 (1.3 g, 9.32 mmol, 2.0 eq) in H 2 O (2 mL) and Pd(dppf)Cl 2 (341 mg, 0.47 mmol, 0.1 eq). The mixture was heated to 110 °C for 2 hours under nitrogen atmosphere. The reaction mixture was cooled to room temperature and poured into water (50 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL) and dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 1:1) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-chloro-4,4'-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (1.2 g). Yield 54% (ESI 472.1 [M+H] +< ).Step 2: ethyl (S)-3-amino-3-(5-chloro-4,4'-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0421]

[0422] To a mixture of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-chloro-4,4'-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (1.2 g, 2.54 mmol, 1.0 eq) in DCM (6 mL) was added HCl-dioxane (4 M, 3 mL, 12 mmol, 4.7 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 80g column (A: water 0.01% TFA, B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(5-chloro-4,4'-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a white solid (900 mg). Yield 96% (ESI 368.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(5-chloro-4-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-chloro-4-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0423]

[0424] A mixture of ethyl (S)-3-(5-bromo-3-chloro-2-fluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (2.0 g, 4.66 mmol, 1.0 eq), mesitylboronic acid (1.5 g, 9.33 mmol, 2.0 eq), K 2 CO 3 (1.29 g, 9.32 mmol, 2.0 eq) and Pd(dppf)Cl 2 (341 mg, 0.466 mmol, 0.1 eq) in dioxane (20 mL) and H 2 O (2 mL) was stirred at 110 °C under nitrogen atmosphere overnight. After completion and cooling to room temperature, the reaction mixture was poured into water (50 mL), extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL) and dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 1:1) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-chloro-4-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a yellow oil (1.9 g). Yield 87% (ESI 468 (M+H) +< ).Step 2: ethyl (S)-3-amino-3-(5-chloro-4-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0425]

[0426] To a mixture of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-chloro-4-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (1.9 g, 4.06 mmol, 1.0 eq) in DCM (20 mL) was added HCl-dioxane (4 M, 3 mL, 12 mmol, 3.0 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 120g column (A: water 10 mM NH 4 HCO 3 , B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(5-chloro-4-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a white solid (1.3 g). Yield 88% (ESI 364.1 (M+H) +< ).Preparation of ethyl (S)-3-(5-bromo-2,3-difluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate Step 1: (R, E)-N-(5-bromo-2,3-difluorobenzylidene)-2-methylpropane-2-sulfinamide

[0427]

[0428] To a mixture of 5-bromo-2,3-difluorobenzaldehyde (4.5 g, 20.36 mmol, 1.0 eq) and (R)-2-methylpropane-2-sulfinamide (2.7 g, 22.40 mmol, 1.1 eq) in anhydrous THF (50 mL) under nitrogen atmosphere was added Ti(OEt) 4 (9.3 g, 40.72 mmol, 2.0 eq) dropwise at room temperature while maintaining the temperature below 30 °C. The reaction mixture was warmed to 35 °C and stirred for 1 hour. LCMS showed that the reaction was completed. Water (50 mL) and EtOAc (50 mL) was added into the mixture and stirred at room temperature for 10 mins. The mixture was filtered and washed with EtOAc (50 mL). The filtrate was separated. The organic layer was washed with water (70 mL) and brine (70 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 4:1) to provide (R, E)-N-(5-bromo-2,3-difluorobenzylidene)-2-methylpropane-2-sulfinamide as a yellow oil (6.0 g). Yield 91% (ESI 325.9 (M+H) +< ).Step 2: ethyl (S)-3-(5-bromo-2,3-difluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate

[0429]

[0430] To a mixture of Zn (3.2 g, 49.2 mmol, 4.00 eq) in anhydrous THF (20 mL) under nitrogen atmosphere was added chlorotrimethylsilane (267 mg, 2.46 mmol, 0.2 eq) dropwise at room temperature. The mixture was stirred at 50 °C for 1 hour under nitrogen atmosphere and cooled to 20-30°C. Ethyl 2-bromoacetate (5.1 g, 30.75 mmol, 2.50 eq) was added dropwise at room temperature under nitrogen atmosphere and then stirred at 60 °C for 1 hour under nitrogen atmosphere. The reaction mixture was cooled to room temperature. A solution of (R,E)-N-(5-bromo-2,3-difluorobenzylidene)-2-methylpropane-2-sulfinamide (4.0 g, 12.3 mmol, 1.00 eq) in anhydrous THF (5 mL) was added dropwise into the mixture at room temperature under nitrogen atmosphere and stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. Water (150 mL) and EtOAc (150 mL) were added into the mixture and stirred at room temperature for 10 mins. The mixture was filtered and washed with EtOAc (50 mL). The filtrate was separated. The organic layer was washed with water (100 mL) and brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 3:1) to provide ethyl (S)-3-(5-bromo-2,3-difluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate as a colorless oil (2.7 g). Yield 53% (ESI 412.0 (M+H) +< ).Preparation of ethyl (S)-3-amino-3-(4,5-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,5-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0431]

[0432] A mixture of ethyl (S)-3-(5-bromo-2,3-difluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (1.0 g, 2.4 mmol, 1.00 eq), K 2 CO 3 (664 mg, 4.8 mmol, 2.0 eq) Pd(dppf)Cl 2 (175 mg, 0.24 mmol, 0.1 eq) and (2,6-dimethylphenyl)boronic acid (720 mg, 4.8 mmol, 2.00 eq) in dioxane (12 mL) and H 2 O (1.2 mL) was stirred at 110 °C under nitrogen atmosphere for 2 hours. LCMS showed that the reaction was completed. The reaction mixture was poured into 50 mL of water and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 2:1) to give desired product ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,5-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoateas a yellow oil (900 mg). Yield 85% (ESI 438.1 (M+H) +< ).Step 2: ethyl (S)-3-amino-3-(4,5-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0433]

[0434] To a mixture of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,5-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (900 mg, 2.06 mmol, 1.0 eq) in DCM (4 mL) was added HCl-dioxane (4 M, 2 mL, 8.0 mmol, 3.88 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 40 g column (A: water / 0.01%TFA, B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(4,5-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a light yellow solid (800 mg). Yield 90% (ESI 334.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4,4',5-trifluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,4',5-trifluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0435]

[0436] A mixture of ethyl (S)-3-(5-bromo-2,3-difluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (1.1 g, 2.68 mmol, 1.00 eq), K 3 PO 4 (1.7 g, 8.04 mmol, 3.00 eq), X-Phos Pd G2 (212 mg, 0.27 mmol, 0.10 eq) and (4-fluoro-2,6-dimethylphenyl)boronic acid (900 mg, 5.36 mmol, 2.00 eq) in THF (10 mL) and H 2 O (2 mL) was stirred at 50 °C under nitrogen atmosphere for 2 hours. LCMS showed that the reaction was completed. The reaction mixture was poured into 50 mL of water and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 1:1) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,4',5-trifluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a brown oil (1 g). Yield 82% (ESI 456.1 (M+H) +< )Step 2: ethyl (S)-3-amino-3-(4,4',5-trifluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0437]

[0438] To a mixture of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,4',5-trifluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (1.0 g, 2.2 mmol, 1.0 eq) in DCM (4 mL) was added HCl-dioxane (4 M, 2 mL, 4.0 mmol, 1.8 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 80g column (A: water 10 mM NH 4 HCO 3 , B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(4,4',5-trifluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate as a white solid (750 mg). Yield 97% (ESI 352.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4,5-difluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0439] Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,5-difluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0440]

[0441] A mixture of ethyl (S)-3-(5-bromo-2,3-difluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (1.5 g, 3.65 mmol, 1.0 eq), mesitylboronic acid(1.2 g, 7.30 mmol, 2.0 eq), K 2 CO 3 (1.5 g, 10.95 mmol, 3.0 eq) and Pd(dppf)Cl 2 (267 mg, 0.365 mmol, 0.1 eq) in dioxane (10 mL) and H 2 O (1 mL) was stirred at 110 °C under nitrogen atmosphere for 1 hour. LCMS showed that the reaction was completed. The mixture was cooled to room temperature, poured into water (30 mL), extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 2:1) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,5-difluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a yellow oil (1.4 g). Yield 85% (ESI 452.2 (M+H) +< ).Step 2: ethyl (S)-3-amino-3-(4,5-difluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0442]

[0443] To a mixture of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,5-difluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate (1.4 g, 3.1 mmol, 1.0 eq) in DCM (20 mL) was added HCl-dioxane (4 M, 2 mL, 8.0 mmol, 2.58 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 120g column (A: water / 0.01%TFA, B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(4,5-difluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a light yellow solid (1.0 g). Yield 93% (ESI 348.1 (M+H) +< ).Preparation of ethyl (S)-3-(5-bromo-2-fluoro-3-(trifluoromethyl)phenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate Step 1: 5-bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde

[0444]

[0445] To a solution of 4-bromo-1-fluoro-2-(trifluoromethyl)benzene (10.0 g, 41.15 mmol, 1.00 eq) in anhydrous THF (50 mL) under nitrogen atmosphere at -78 °C was added Lithium diisopropylamide (2.0 M, 30.9 mL, 61.73 mmol, 1.50 eq) dropwise and stirred at -78 °C for 1 hour under nitrogen atmosphere. DMF (15 mL) was added dropwise and the mixture was stirred at -78 °C for 1 hour. The mixture was quenched with 1M HCl aqueous solution (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue obtained was purified by silica gel column (pet ether: EtOAc 20:1) to provide 5-bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde as a white solid (8.0 g). Yield 72%. 1< H NMR (400 MHz, CDCl 3 ) δ 10.34 (s, 1H), 8.19 (dd, J = 5.4, 2.4 Hz, 1H), 7.98 (dd, J = 6.1, 2.5 Hz, 1H).Step 2: (R, E)-N-(5-bromo-2-fluoro-3-(trifluoromethyl)benzylidene)-2-methylpropane-2-sulfinamide

[0446]

[0447] To a mixture of 5-bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde (8.0 g, 29.50 mmol, 1.00 eq) and (R)-2-methylpropane-2-sulfinamide (3.9 g, 32.45 mmol, 1.1 eq) in anhydrous THF (100 mL) under nitrogen atmosphere was added Ti(OEt) 4 (13.0 g, 59.00 mmol, 2.00 eq) dropwise at room temperature and maintained the temperature below 30 °C. The reaction mixture was stirred at room temperature for 1 hour under nitrogen atmosphere. LCMS showed that the reaction was completed. Water (100 mL) and EtOAc (100 mL) was added into the mixture and stirred at room temperature for 5 mins. The mixture was filtered and washed with EtOAc (50 mL). The filtrate was separated. The organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 5:1) to provide (R, E)-N-(5-bromo-2-fluoro-3-(trifluoromethyl)benzylidene)-2-methylpropane-2-sulfinamide as a yellow oil (8.0 g). Yield 72% (ESI 373.9 (M+H) +< ).Step 3: ethyl (S)-3-(5-bromo-2-fluoro-3-(trifluoromethyl)phenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate

[0448]

[0449] To a mixture of Zn (5.6 g, 85.6 mmol, 4.00 eq) in anhydrous THF (100 mL) under nitrogen atmosphere was added chlorotrimethylsilane (465 mg, 4.28 mmol, 0.2 eq) dropwise at room temperature. The mixture was stirred at 45 °C for 1 hour under nitrogen atmosphere and cooled to 20-30°C. Ethyl 2-bromoacetate (8.9 g, 53.5 mmol, 2.50 eq) was added dropwise at room temperature. The reaction mixture was stirred at 50 °C for 1 hour under nitrogen atmosphere and then cooled to room temperature. A solution of (R,E)-N-(5-bromo-2-fluoro-3-(trifluoromethyl)benzylidene)-2-methylpropane-2-sulfinamide (8.0 g, 21.4 mmol, 1.00 eq) in anhydrous THF (10 mL) was added dropwise into the mixture at room temperature under nitrogen atmosphere. The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. Water (100 mL) and EtOAc (100 mL) was added into the mixture and stirred at room temperature for 5 mins. The mixture was filtered and washed with EtOAc (100 mL). The filtrate was separated. The organic layer was washed with water (100 mL) and brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 4:1) to provide ethyl (S)-3-(5-bromo-2-fluoro-3-(trifluoromethyl)phenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate as a colorless oil (6.3 g). Yield 64% (ESI 462.0 (M+H) +< ).Preparation of ethyl (S)-ethyl 3-amino-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0450]

[0451] To a solution of ethyl (S)-3-(5-bromo-2-fluoro-3-(trifluoromethyl)phenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (3 g, 6.49 mmol) and (2,6-dimethylphenyl)boronic acid (1.46 g, 9.73 mmol) in Dioxane (24 mL) was added a solution of Cs2CO3 (4.23 g, 12.98 mmol) in Water (8 mL). The reaction was purged with N2 for 5 min, followed by addition of PdCl2(dppf) (0.712 g, 0.973 mmol) and another N2 purge for 1 min. The reaction was stirred at 70C for 4 hours. The reaction mixture was diluted into 250 mL EtOAc, then washed with 1N HCl (250 mL), Sat. NaHCO3 (205 mL) and Brine (250 mL). The residue was concentrated and purified by silica gel chromatography to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate (2.71 g). Yield 86% (ESI 488 (M+H)+).Step 2: (S)-ethyl 3-amino-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate

[0452]

[0453] To a solution of (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate (0.93 g, 1.9 mmol, 1.00 eq) in DCM (8 mL) was added HCl-dioxane (4M, 1.9 mL, 7.6 mmol, 4 eq) and stirred at room temperature for 2 hours. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 120 g column (A: water / 0.01%TFA, B: MeOH, 0~100%) to provide (R)-ethyl 3-amino-3-(4-fluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate as a yellow solid (0.6 g). Yield 82% (ESI 384.1 (M+H) +< ).Preparation of ethyl (S)-3-amino-3-(4,4'-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,4'-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0454]

[0455] A mixture of ethyl (S)-3-(5-bromo-2-fluoro-3-(trifluoromethyl)phenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (2.0 g, 4.3 mmol, 1.00 eq), K 2 CO 3 (1.8 g, 12.9 mmol, 3.00 eq), Pd(dppf)Cl 2 (315 mg, 0.43 mmol, 0.10 eq) and (4-fluoro-2,6-dimethylphenyl)boronic acid (1.1 g, 6.45 mmol, 1.50 eq) in dioxane (50 mL) and H 2 O (5 mL) was stirred at 110 °C for 2 hours under nitrogen atmosphere. LCMS showed that the reaction was completed. The reaction mixture was poured into 50 mL of water, extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (15 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 3:1) to provideethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,4'-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (1.4 g). Yield 64% (ESI 506.0 (M+H) +< )Step 2: ethyl (S)-3-amino-3-(4,4'-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0456]

[0457] To a mixture of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(4,4'-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate (1.4 g, 2.77 mmol, 1.0 eq) in DCM (10 mL) was added HCl-dioxane (4 M, 6 mL, 24.0 mmol, 8.66 eq). The mixture was stirred at room temperature for 1 hour. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 120g column (A: water / 0.01%TFA, B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(4,4'-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (880 mg). Yield 79% (ESI 402.1 [M+H] +< ).Preparation of (S)-ethyl 3-amino-3-(4-fluoro-2',3',5,6'-tetramethylbiphenyl-3-yl)propanoate Step 1: (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(4-fluoro-2',3',5,6'-tetramethylbiphenyl-3-yl)propanoate

[0458]

[0459] To a mixture of (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(2-fluoro-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (3.0 g, 6.7 mmol), 2,3,6-trimethylphenyl trifluoromethanesulfonate (2.2 g, 8.0 mmol) and K 3 PO 4 (4.3 g, 20.1 mmol) in dioxane (30 mL) and H 2 O (3 mL) was added X-Phos Pd G2 (550 mg, 0.7 mmol). The mixture was heated to 110°C for 1 hr under nitrogen atmosphere. Water (50 mL) was added and the solution was extracted with EtOAc (60 mL x 3). The combined organic phases were concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 2:1) to provide (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(4-fluoro-2',3',5,6'-tetramethylbiphenyl-3-yl)propanoate as a dark solid (1.7 g). Yield 57 % (ESI 344.1 [M+H-100] +< ).Step 2: (S)-ethyl 3-amino-3-(4-fluoro-2',3',5,6'-tetramethylbiphenyl-3-yl)propanoate

[0460]

[0461] To a mixture of (S)-ethyl 3-(tert-butoxycarbonylamino)-3-(4-fluoro-2',3',5,6'-tetramethylbiphenyl-3-yl)propanoate (1.7 g, 3.8 mmol) in DCM (2 mL) was added HCl-dioxane (4M, 5 mL, 20.0 mmol) and the mixture was stirred at rt for 30 minutes. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 120g column (A: water 10mM NH 4 HCO 3 , B: CH 3 CN, 0~100%) to provide (S)-ethyl 3-amino-3-(4-fluoro-2',3',5,6'-tetramethylbiphenyl-3-yl)propanoate as a colorless oil (1.0 g). Yield 76 % (ESI 344.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4-fluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)phenyl)propanoate

[0462]

[0463] A mixture of ethyl (S)-3-(5-bromo-2-fluoro-3-(trifluoromethyl)phenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (2.8 g, 6.1 mmol), KOAc (1.8 g, 18.3mmol), Pd(dppf)Cl 2 (446 mg, 0.61 mmol) and (4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.3 g, 9.15 mmol) in dioxane (30 mL) was stirred at 100 °C for 2 hours under nitrogen. The reaction mixture was poured into 50 mL of water and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na 2 SO 4 , filtered and the filtrate concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 3:1) to provideethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)phenyl)propanoate as a colorless oil (2.6 g). Yield 84 % (ESI 510.1 (M+H) +< )Step 2: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(3',4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0464]

[0465] A mixture of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)phenyl)propanoate (600 mg, 1.2 mmol), K 2 CO 3 (497mg, 3.6 mmol), Pd(dppf)Cl 2 (88 mg, 0.12 mmol) and 2-bromo-4-fluoro-1,3-dimethylbenzene (363.6 mg, 1.8 mmol) in dioxane (6 mL) and H 2 O (0.6 mL) was stirred at 110 °C under nitrogen for 2 hours. The reaction mixture was poured into 20 mL of water and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 3:1) to provideethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(3',4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (460 mg). Yield 77 % (ESI 506.1 (M+H) +< )Step 3: ethyl (S)-3-amino-3-(3',4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0466]

[0467] To a mixture of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(3',4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate (460 mg, 0.91 mmol) in EtOH (5 mL) was added HCl-dioxane (4 M, 2 mL, 8.0 mmol). The mixture was stirred at room temperature for 1 hour. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 40g column (A: water / 0.05%TFA, B: MeOH, 0~100%) to provideethyl (S)-3-amino-3-(3',4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (230 mg). Yield 63% (ESI 402.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4-fluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate Step 1: ((S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(4-fluoro-3'-methoxy-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate

[0468]

[0469] A mixture of (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)phenyl)propanoate (600 mg, 1.18 mmol), K 2 CO 3 (488 mg, 3.54 mmol), Pd(dppf)Cl 2 (43 mg, 0.06 mmol) and 2-bromo-4-methoxy-1,3-dimethylbenzene (300 mg, 1.42 mmol) in dioxane (10 mL) and H 2 O (1 mL) was stirred at 110 °C under nitrogen atmosphere for 1 hour. The reaction mixture was poured into 50 mL of water and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 3:2) to provide (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(4-fluoro-3'-methoxy-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate as a colorless oil (400 mg). Yield 65 % (ESI 518.3 (M+H) +< )Step 2: (S)-ethyl 3-amino-3-(4-fluoro-3'-methoxy-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate

[0470]

[0471] To a mixture of (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(4-fluoro-3'-methoxy-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate (400 mg, 0.77 mmol) in DCM (2 mL) was added HCl-dioxane (4 M, 1 mL, 4.0 mmol). The mixture was stirred at room temperature for 1 hour. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 40g column (A: water 10mM NH 4 HCO 3 , B: CH 3 CN, 0~100%) to provide (S)-ethyl 3-amino-3-(4-fluoro-3'-methoxy-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate (200 mg). Yield 63% (ESI 414.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(4-fluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate Step 1: 2,3,6-trimethylphenyl trifluoromethanesulfonate

[0472]

[0473] To a mixture of 2,3,6-trimethylphenol (5 g, 36.8 mmol), NEt 3 (9.3 g, 92.0 mmol) in DCM (100 mL) was added Tf 2 O (15.6 g, 55.2 mmol) at 0 °C dropwise and stirred at room temperature for 3 hours. The reaction mixture was poured into 100 mL of water and extracted with DCM (100 x 3mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel column (pet ether) to provide 2,3,6-trimethylphenyl trifluoromethanesulfonate as a colorless oil (8 g). Yield 80 % (ESI 269.3 (M+H) +< ).Step 2: (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(4-fluoro-2',3',6'-trimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate

[0474]

[0475] To a mixture of (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)phenyl)propanoate (400 mg, 0.79 mmol), 2,3,6-trimethylphenyl trifluoromethanesulfonate (253 mg, 0.94 mmol) and K 3 PO 4 (502 mg, 2.37 mmol) in dioxane (10 mL) and H 2 O (1 mL) was added Xphos Pd G2 (63 mg, 0.08 mmol). The mixture was heated to 110°C for 30 mins under nitrogen atmosphere. Water (20 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic phases were concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 2:1) to provide (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(4-fluoro-2',3',6'-trimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate as a dark solid (300 mg). Yield 76 % (ESI 502.1 [M-100+H] +< ).Step 3: (S)-ethyl 3-amino-3-(4-fluoro-2',3',6'-trimethyl-3-(trifluoromethyl)biphenyl-3-yl)propanoate

[0476]

[0477] To a mixture of (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(4-fluoro-2',3',6'-trimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate (300 mg, 0.6 mmol) in DCM (1mL) was added HCl-dioxane (4N, 1 mL, 2.5 mmol) and the mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 40g column (A: water 10mM NH 4 HCO 3 , B: CH 3 CN, 0~100%) to provide (S)-ethyl 3-amino-3-(4-fluoro-2',3',6'-trimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate as a colorless oil (170 mg). Yield 71% (ESI 398.1(M+H) +< ).Preparation of ethyl (S)-3-amino-3-(4-fluoro-2',4',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate Step 1: (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(4-fluoro-2',4',6'-trimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate

[0478]

[0479] To a mixture of (S)-ethyl 3-(5-bromo-2-fluoro-3-(trifluoromethyl)phenyl)-3-((R)-1,1-dimethylethylsulfinamido)propanoate (461 mg, 1.0 mmol), mesitylboronic acid (197 mg, 1.2 mmol) and K 2 CO 3 (414 mg, 3.0 mmol) in dioxane (10 mL) and H 2 O (1 mL) was added Pd(dppf)Cl 2 (73 mg, 0.1 mmol). The mixture was heated to 110°C for 2 hrs under nitrogen atmosphere. Water (20 mL) was added and the mixture was extracted with EtOAc (20 mL x 3). The combined organic phases were concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 2: 1) to provide (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(4-fluoro-2',4',6'-trimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate as a dark solid (400 mg). Yield 80 % (ESI 502.1 [M-100+H] +< ).Step 2: (S)-ethyl 3-amino-3-(4-fluoro-2',4',6'-trimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate

[0480]

[0481] To a mixture of (S)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-3-(4-fluoro-2',4',6'-trimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate (400 mg, 0.8 mmol) in DCM (1mL) and EtOH (2mL) was added HCl-dioxane (4M, 2 mL, 8 mmol) and stirred at rt for 0.5 hr. The mixture was concentrated in vacuo to provide theproduct as a yellow oil (350 mg, crude).(ESI 398.1[M+H] +< ).Preparation of ethyl (3S)-3-amino-3-(2,4,4'-trifluoro-2',3',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate Step 1: 2,6-dibromo-4-fluoro-3-methylaniline

[0482]

[0483] To a mixture of 4-fluoro-3-methylaniline (50.0 g, 400 mmol,) in MeOH (120 mL) and DCM (120 mL) was added bromine (52 mL, 1.0 mol) dropwise at room temperature over 1.5 hour and stirred at room temperature for 4 hours. 1N Na 2 S 2 O 3 aqueous solution (300 mL) and ethyl acetate (500 mL) was added and stirred for 10 mins, then carefully basified with 1N Na 2 CO 3 aqueous solution (300 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 × 100 mL). The combined organic layers were washed with 1N Na 2 S 2 O 3 aqueous solution (300 mL) and brine (200 mL) dried over Na 2 SO 4 , filtered and concentrated in vacuo to provide 2,6-dibromo-4-fluoro-3- methylaniline as a white solid (80 g). Yield 70.7 % (ESI 284.0[M+H] +< ).Step 2: 4-fluoro-2,3,6-trimethylaniline

[0484]

[0485] To a solution of ethyl 2,6-dibromo-4-fluoro-3-methylaniline (50.0 g, 273 mmol) in dioxane (500.0 mL) and water (50 mL) was added methylboronic acid (49.0 g, 819 mmol), K 2 CO 3 (111.0 g, 819 mmol) and 1,1'-Bis(diphenylphosphino) ferrocene-palladium(II)dichloride dichloromethane complex (10.0 g, 13.65 mmol). The mixture was stirred at 110°C overnight. The reaction was poured into water (500 mL) and extracted with Ethyl Acetate (500 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 1:5) to provide 4-fluoro-2,3,6-trimethylaniline as a colorless oil (20.0 g). Yield 47.6 % (ESI 154.3 (M+H) +< )Step 3: 2-bromo-5-fluoro-1,3,4-trimethylbenzene

[0486]

[0487] To a mixture of 4-fluoro-2,3,6-trimethylaniline (3.8 g, 24.8 mmol) in MeCN (30 mL) was added t-BuONO (3.8 g, 37.2 mmol) at 0°C, then CuBr(4.3 g, 29.7 mmol) was added. The mixture was stirred at 60°C for 2 hours. The reaction mixture was concentrated in vacuo and the residue was purified by silica gel column (pet ether) to provide 2-bromo-5-fluoro-1,3,4-trimethylbenzene as a colorless oil (1.3 g). Yield 33.9 % .Step 4: ethyl (3S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2,4,4'-trifluoro-2',3',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0488]

[0489] A mixture of (3-((S)-1-(((R)-tert-butylsulfinyl)amino)-3-ethoxy-3-oxopropyl)-2,4-difluoro-5-(trifluoromethyl)phenyl)boronic acid (1.5 g, 3.3 mmol), 2-bromo-5-fluoro-1,3,4-trimethylbenzene (950 mg, 4.3 mmol), K 3 PO 4 (2.1 g, 9.9 mmol), X-Phos Pd G2 (285 mg, 0.33 mmol) in dioxane (10 mL) and H 2 O (2 mL) was stirred at 110°C for 2h under N2 atmosphere. The mixture was poured into water (100 mL) and extracted with EtOAc (100 mL X 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 1:1) to provide ethyl (3S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2,4,4'-trifluoro-2',3',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate (380 mg) as a yellow oil. Yield 21.3% ( ESI 538.0(M+H) +< ).Step 5: ethyl (3S)-3-amino-3-(2,4,4'-trifluoro-2',3',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0490]

[0491] To a solution of ethyl (3S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2,4,4'-trifluoro-2',3',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate (380 mg, 0.70 mmol) in DCM (5 mL) was added HCl-dioxane (4 M, 5 mL) and stirred at at room temperature for 1 hour. The mixture was concentrated in vacuo to provide ethyl (3S)-3-amino-3-(2,4,4'-trifluoro-2',3',6'-trimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoateas a yellow oil (340 mg) used directly in the next step without further purification. Yield 100% (ESI 434.2 [M+H] +< ).Preparation of ethyl (3S)-3-amino-3-(3'-cyclopropyl-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate Step 1: 3-bromo-2,6-dimethylaniline

[0492]

[0493] To a mixture of 1-bromo-2,4-dimethyl-3-nitrobenzene (3.0 g, 13.0 mmol) in MeOH (30 mL) and H 2 O (3 mL) at 0°C was added NH 4 Cl (2.1 g, 39.0 mmol) and Zn (8.5 g, 130.0 mmol). The mixture was stirred at room temperature for 20 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 3:2) to provide 3-bromo-2,6-dimethylaniline as a brown solid (2.0 g). Yield 77 % (ESI 200.1 [M+H] +< ).Step 2: 3-cyclopropyl-2,6-dimethylaniline

[0494]

[0495] A mixture of 3-bromo-2,6-dimethylaniline (1.5 g, 7.5 mmol), cyclopropylboronic acid (3.2 g, 37.5 mmol), X-Phos (357.5 mg, 0.75 mmol), Pd 2 (dba) 3 (343.4 mg, 0.38 mmol) and K 3 PO 4 (4.8 g, 22.5 mmol) in 1,4-dioxane (10 mL) and water (1 mL) was stirred at 110 °C for overnight under nitrogen atmosphere. The reaction mixture was cooled to room temperature, filtered through a pad of Celite and the filtrate was concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 5:1) to provide 3-cyclopropyl-2,6-dimethylaniline as a colorless oil (1.1 g). Yield 91 % (ESI 162.2 [M+H] +< ).Step 3: 1-cyclopropyl-3-iodo-2,4-dimethylbenzene

[0496]

[0497] To a mixture of 3-cyclopropyl-2,6-dimethylaniline (1.1 g, 6.8 mmol) in CH 3 CN (10 mL) and H 2 O (1 mL) was added p-toluenesulphonic acid (5.9 g, 34.0 mmo). The mixture was stirred at 0 °C for 10 mins under under nitrogen atmosphere. A solution of NaNO 2 (703.8 mg, 10.2 mmol) in H 2 O (2 mL) was added dropwise and the mixture was stirred 0 °C for 1 hour. Then KI (3.4 g, 20.4 mmol) was added to the reaction mixture and stirred at 0 °C for 2 hours. After completion, water (20 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic phases were washed with brine (20 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (petroleum ether) to provide 1-cyclopropyl-3-iodo-2,4-dimethylbenzene as a colorless oil (240 mg) used without further purification. Yield 13%. 1< H NMR (400 MHz, CDCl 3 ) δ 6.98 (d, J = 7.8 Hz, 1H), 6.93 (d, J = 7.8 Hz, 1H), 2.63 (s, 3H), 2.44 (s, 3H), 1.94 - 1.85 (m, 1H), 0.95 - 0.86 (m, 2H), 0.62 - 0.55 (m, 2H).Step 4: ethyl (3S)-3-(((R)-tert-butylsulfinyl)amino)-3-(3'-cyclopropyl-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0498]

[0499] A mixture of (3-((S)-1-(((R)-tert-butylsulfinyl)amino)-3-ethoxy-3-oxopropyl)-2,4-difluoro-5-(trifluoromethyl)phenyl)boronic acid (350 mg, 0.79 mmol), 1-cyclopropyl-3-iodo-2,4-dimethylbenzene (240 mg, 0.88 mmol), X-Phos Pd G2 (62.1 mg, 0.08 mmol) and K 3 PO 4 (503.1 mg, 2.37 mmol) in 1,4-dioxane (10 mL) and water (1 mL) was stirred at 105 °C for 1 hour under nitrogen atmosphere. TheThe reaction mixture was cooled to room temperature, filtered through a pad of Celite and the filtrate was concentrated in vacuo. The residue was purified by silica gel column (petroleum ether: EtOAc 3:2) to provide ethyl (3S)-3-(((R)-tert-butylsulfinyl)amino)-3-(3'-cyclopropyl-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate as a brown oil (270 mg). Yield 63% (ESI 546.2 [M+H] +< ).Step 5: ethyl (3S)-3-amino-3-(3'-cyclopropyl-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0500]

[0501] To a mixture of ethyl (3S)-3-(((R)-tert-butylsulfinyl)amino)-3-(3'-cyclopropyl-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate (270.0 mg, 049 mmol) in EtOH (2 mL) was added HCl-dioxane (4 M, 2 mL, 8.0 mmol). The mixture was stirred at room temperature for 1 hour. The mixture was concentrated in vacuo to provide ethyl (3S)-3-amino-3-(3'-cyclopropyl-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate as a colorless oil (210.0 mg), used without further purification. Yield 96% (ESI 442.2 [M+H] +< ).Preparation of (3S)-ethyl 3-amino-3-(3'-cyclopropoxy-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate Step 1: 2-bromo-4-cyclopropoxy-1,3-dimethylbenzene

[0502]

[0503] A mixture of 3-bromo-2,4-dimethylphenol (1.0 g, 4.98 mmol), bromocyclopropane (3.0 g, 24.8 mmol) and Cs 2 CO 3 (4.9 g, 14.9 mmol) in NMP (20 mL) was stirred at 140 °C for 20 hours. The mixture was cooled to room temperature and poured into NH 4 Cl (aq.) (20 mL). The solution was extracted with EtOAc (200 mL x 3). The combined organic layer was washed with brine (20 mL x 2), dried over anhydrous Na 2 SO 4 filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether) to provide 2-bromo-4-cyclopropoxy-1,3-dimethylbenzene as a colorless oil (1.0 g). Yield 83 % . 1< H NMR (400 MHz, CDCl 3 ) δ 7.07 (d, J = 8.4 Hz, 1H), 7.04 (d, J = 8.6 Hz, 1H), 3.75 - 3.65 (m, 1H), 2.35 (s, 3H), 2.27 (s, 3H), 0.79 - 0.73 (m, 4H).Step 2: (3S)-ethyl 3-(3'-cyclopropoxy-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)-3-((R)-1,1-dimethylethylsulfinamido)propanoate

[0504]

[0505] To a mixture of 3-((S)-1-((R)-1,1-dimethylethylsulfinamido)-3-ethoxy-3-oxopropyl)-2,4-difluoro-5-(trifluoromethyl)phenylboronic acid (400 mg, 0.9 mmol), 2-bromo-4-cyclopropoxy-1,3-dimethylbenzene (260 mg, 1.1 mmol) and K 3 PO 4 (636 mg, 3.0 mmol) in dioxane (5 mL) and H 2 O (0.5 mL) was added X-Phos Pd G2 (79 mg, 0.1 mmol). The mixture was heated to 110°C for 1 hr under nitrogen atmosphere. Water (10 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic phases were concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 2:1) to provide (3S)-ethyl 3-(3'-cyclopropoxy-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)-3-((R)-1,1-dimethylethylsulfinamido)propanoate as a dark solid (300 mg). Yield 59 % (ESI 562.1 [M+H] +< ).Step 3: (3S)-ethyl 3-amino-3-(3'-cyclopropoxy-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate

[0506]

[0507] To a mixture of (3S)-ethyl 3-(3'-cyclopropoxy-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)-3-((R)-1,1-dimethylethylsulfinamido)propanoate (300 mg, 0.53 mmol) in DCM (1 mL) was added 4M HCl-dioxane (0.5 mL, 2.0 mmol). The mixture was stirred at rt for 0.5 hr. The mixture was concentrated in vacuo and the residue was purified by reverse phase on a C18 / 120g column (A: water 10mM NH 4 HCO 3 , B: CH 3 CN, 0~100%) to provide (3S)-ethyl 3-amino-3-(3'-cyclopropoxy-2,4-difluoro-2',6'-dimethyl-5-(trifluoromethyl)biphenyl-3-yl)propanoate as a colorless oil (150 mg). Yield 62 % (ESI 458.1 [M+H] +< ).Preparation of ethyl (S)-3-amino-3-(2,4-difluoro-2',6'-dimethyl-4',5-bis(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2,4-difluoro-2',6'-dimethyl-4',5-bis(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0508]

[0509] A mixture of (3-((S)-1-(((R)-tert-butylsulfinyl)amino)-3-ethoxy-3-oxopropyl)-2,4-difluoro-5-(trifluoromethyl)phenyl)boronic acid (900 mg, 2.0 mmol), K 3 PO 4 (1.06 g, 5.0 mmol), X-Phos Pd G2 (157 mg, 0.2 mmol) and 2-bromo-1,3-dimethyl-5-(trifluoromethyl)benzene (607 mg, 2.4 mmol) in dioxane (20 mL) and H 2 O (2 mL) was stirred at 100 °C under nitrogen atmosphere for 2 hours. The reaction mixture was poured into 50 mL of water and extracted with EtOAc (50 x 3mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 3:2) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2,4-difluoro-2',6'-dimethyl-4',5-bis(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate as a yellow solid (730 mg). Yield 63.6% (ESI 574.2 (M+H) +< )Step 2: ethyl (S)-3-amino-3-(2,4-difluoro-2',6'-dimethyl-4',5-bis(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate

[0510]

[0511] To a mixture of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(2,4-difluoro-2',6'-dimethyl-4',5-bis(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate (730 mg, 1.27 mmol) in DCM (4 mL) was added HCl-dioxane (4 M, 1 mL, 4.0 mmol). The mixture was stirred at room temperature for 1 hour. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 40g column (A: water 10 mM NH 4 HCO 3 , B: CH 3 CN, 0~100%) to provide ethyl (S)-3-amino-3-(2,4-difluoro-2',6'-dimethyl-4',5-bis(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoate (280 mg). Yield 47% (ESI 470.0 [M+H] +< ).Preparation of ethyl (S)-3-(3-bromo-5-cyclopropyl-2,6-difluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate Step 1: 5-cyclopropyl-2,4-difluoroaniline

[0512]

[0513] To a solution of 5-bromo-2,4-difluoroaniline (15.0 g, 72.1 mmol) in Toluene (50 mL) and H 2 O (55 mL) under nitrogen atmosphere at room temperature was added X-phos (1.7 g, 3.6 mmol), Pd 2 dba 3 (3.3 g, 3.6 mmol), cyclopropylboronic acid (12.4 g, 144.2 mmol) and K 3 PO 4 (30.9 g, 144.2 mmol) and stirred at 100 °C for 16 hours under nitrogen atmosphere. The reaction was filtered and washed with EtOAc (50 mL). The filtrate was concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 10:1) to provide 5-cyclopropyl-2,4-difluoroaniline as white solids (12.0 g). Yield 92 % (ESI 170.2 (M+H) +< ).Step 2: 1-bromo-5-cyclopropyl-2,4-difluorobenzene

[0514]

[0515] To a mixture of 5-cyclopropyl-2,4-difluoroaniline (12.0 g, 71.0 mmol) and CuBr (25.5 g, 177.5 mmol) in ACN (200 mL) and H 2 O (40 mL) at 0 °C was added p-Toluenesulfonic acid (54.0 g, 284.0 mmol) and then stirred for 1 hour. To the mixture was added a solution of NaNO 2 (7.3 g, 106.5 mmol) in H 2 O (20 mL) dropwise. The mixture was extracted with EtOAc (80 mL x 3). The organic layer was washed with brine, dried over Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether) to provide 1-bromo-5-cyclopropyl-2,4-difluorobenzene (7.0 g, yield: 42%) as a colorless oil .Step 3: 3-bromo-5-cyclopropyl-2,6-difluorobenzaldehyde

[0516]

[0517] To a solution of 1-bromo-5-cyclopropyl-2,4-difluorobenzene(7.0 g, 30.0 mmol) in THF (50 mL) at -78 °C was added LDA(22.6 mL, 45.2 mmol) dropwise and stirred at -78 °C for 1h. Then DMF(5 mL) was added dropwise and stirred at -78 °C for another 1h. The reaction mixture was warmed to r.t. and quenched with saturated NH 4 Cl (20 mL) aquous solution and stirred at room teperature for 30 mins. The the mixture was extracted with EtOAc(100 mL x 3). The organic layer was washed with brine, dried over Na 2 SO 4 , filtered and concentrated in vacuo to provide 3-bromo-5-cyclopropyl-2,6-difluorobenzaldehyde as a yellow oil without further purification (6.5 g, yield:88%).Step 4: (R,E)-N-(3-bromo-5-cyclopropyl-2,6-difluorobenzylidene)-2-methylpropane-2-sulfinamide

[0518]

[0519] To a mixture of 3-bromo-5-cyclopropyl-2,6-difluorobenzaldehyde (7.3 g, 29.4 mmol) and (R)-2-methylpropane-2-sulfinamide (4.3 g, 35.3 mmol) in anhydrous THF (50 mL) under nitrogen atmosphere was added Ti(OEt) 4 (10.0 g, 44.1 mmol) dropwise at room temperature. During which the temperature was maintained below 30 °C. The reaction mixture was stirred at room temperature for 1 hour under nitrogen atmosphere. Water (100 mL) and EtOAc (100 mL) was added into the mixture and stirred at room temperature for 5 mins. The mixture was filtered and washed with EtOAc (50 mL). The organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 5:1) to provide (R,E)-N-(3-bromo-5-cyclopropyl-2,6-difluorobenzylidene)-2-methylpropane-2-sulfinamide as a yellow oil (6.3 g). Yield 61% (ESI 364.0 (M+H) +< , 366.0 (M+2+H) +< ).Step 5: ethyl (S)-3-(3-bromo-5-cyclopropyl-2,6-difluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate

[0520]

[0521] To a mixture of Zn (10.0 g, 149.3 mmol) in anhydrous THF (100 mL) under nitrogen atmosphere was added chlorotrimethylsilane (1.0 g, 9.8 mmol) dropwise at room temperature. The mixture was stirred at 50 °C for 1 hour under nitrogen atmosphere. This mixture was then cooled to 20-30°C. Ethyl 2-bromoacetate (12.4 g, 74.3 mmol) was added dropwise at room temperature and the mixture was stirred at 50 °C for 1 hour under nitrogen atmosphere. The reaction mixture was cooled to room temperature. A solution of (R,E)-N-(3-bromo-5-cyclopropyl-2,6-difluorobenzylidene)-2-methylpropane-2-sulfinamide (9.0 g, 24.7 mmol) in anhydrous THF (10 mL) was added dropwise into the mixture at room temperature and the mixture was stirred at room temperature for 1 hour. Water (100 mL) and EtOAc (100 mL) was added into the mixture and stirred at room temperature for 5 mins. The mixture was filtered and washed with EtOAc (100 mL x 2). The organic layer was washed with water (100 mL) and brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel column (pet ether: EtOAc 2:1) to provide ethyl (S)-3-(3-bromo-5-cyclopropyl-2,6-difluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate as a colorless oil (7.1 g). Yield 78 % (ESI 452.0 (M+H) +< ,454.0(M+2+H) +< ).Preparation of ethyl (S)-3-amino-3-(5-cyclopropyl-2,4-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-cyclopropyl-2,4-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0522]

[0523] A mixture of ethyl (S)-3-(3-bromo-5-cyclopropyl-2,6-difluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (800.0 mg, 1.77 mmol), (2,6-dimethylphenyl)boronic acid (380.0 mg, 2.3 mmol), X-Phos Pd G2 (133.0 mg, 0.17 mmol) and K 3 PO 4 (1.1 g, 5.31 mmol) in Toluene (7 mL) and H 2 O (0.7 mL) was stirred at 100°C for 4 hours under a nitrogen atmosphere. The reaction was concentrated in vacuo and the residue purified by silica gel column (pet ether:EtOAc = 3:1) to provide ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-cyclopropyl-2,4-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (700.0 mg, Yield 83%) as a light yellow foam (ESI 478.2 [M+H] +< ).Step 2: ethyl (S)-3-amino-3-(5-cyclopropyl-2,4-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0524]

[0525] To the solution of ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-cyclopropyl-2,4-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate (700.0 mg, 1.47 mmol) in DCM (8 mL) was added HCl-dioxane (4M, 1.9 mL, 7.6 mmol) and stirred at room temperature for 1 hour. The mixture was concentrated in vacuo and the residue was purified by reverse phase HPLC on a C18 / 120 g column (A: water / 0.01%TFA, B: MeOH, 0~100%) to provide ethyl (S)-3-amino-3-(5-cyclopropyl-2,4-difluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate hydrochloride as a yellow solid (500 mg). Yield 91% (ESI 374.2 (M+H) +< ).Preparation of ethyl (S)-3-amino-3-(5-cyclopropyl-2,4-difluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: (S)-ethyl 3-(5-cyclopropyl-2,4-difluoro-2',4',6'-trimethylbiphenyl-3-yl)-3-((R)-1,1-dimethylethylsulfinamido)propanoate

[0526]

[0527] To a mixture of (S)-ethyl 3-(3-bromo-5-cyclopropyl-2,6-difluorophenyl)-3-((R)-1,1-dimethylethylsulfinamido)propanoate (600 mg, 1.3 mmol), mesitylboronic acid (246 mg, 1.5 mmol) and K 3 PO 4 (848 mg, 43.0 mmol) in dioxane (10 mL) and H 2 O (1 mL) was added X-Phos Pd G2 (79 mg, 0.1 mmol). The mixture was heated to 110°C for 2 hrs under a nitrogen atmosphere. Water (20 mL) was added and the solution was extracted with EtOAc (20 mL x 3). The combined organic phases were concentrated in vacuo and the residue was purified by silica gel column (pet ether: EtOAc 2:1) to provide (S)-ethyl 3-(5-cyclopropyl-2,4-difluoro-2',4',6'-trimethylbiphenyl-3-yl)-3-((R)-1,1-dimethylethylsulfinamido)propanoate as a dark solid (400 mg). Yield 80 % (ESI 492.1 [M-100+H] +< ).Step 2: ethyl (S)-3-amino-3-(5-cyclopropyl-2,4-difluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0528]

[0529] To a mixture of (S)-ethyl 3-(5-cyclopropyl-2,4-difluoro-2',4',6'-trimethylbiphenyl-3-yl)-3-((R)-1,1-dimethylethylsulfinamido)propanoate (550 mg, 1.12 mmol) in DCM (1mL) and EtOH (2mL) was added 4M HCl-dioxane (2 mL, 5.0 mmol) and the mixture was stirred at rt for 0.5 hr. Then the mixture was concentrated in vacuo to provide ethyl (S)-3-amino-3-(5-cyclopropyl-2,4-difluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-3-yl)propanoate as a yellow oil (360 mg, crude) used directly in the next reaction. (ESI 388.1(M+H) +< ).Preparation of ethyl (S)-3-amino-3-(5-cyclopropyl-2,4,4'-trifluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate Step 1: ethyl (S)-3-(((R)-tert-butylsulfinyl)amino)-3-(5-cyclopropyl-2,4,4'-trifluoro-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)propanoate

[0530]

[0531] To a mixture of ethyl (S)-3-(3-bromo-5-cyclopropyl-2,6-difluorophenyl)-3-(((R)-tert-butylsulfinyl)amino)propanoate (700 mg, 1.55 mmol), 4-fluoro-2,6-dimethylphenylboronic acid (260 mg, 1.55 mmol), and K 3 PO 4 (657 mg, 3.1 mmol) in 1,4-dioxane (5 mL) and water (0.5 mL) was added X-Phos Pd G2 (117 mg, 0.16 mmol). The mixture was stirred a...

Claims

1. A compound selected from the group consisting of: and or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, as the active pharmaceutical ingredient.

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, for use as a medicament.

4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, for use in a method of treating inflammatory bowel disease, ulcerative colitis, or Crohn's disease.